Allele-specific therapy for huntington disease haplotypes

ABSTRACT

The present invention relates to compositions and methods of use thereof for inhibiting mutant HTT mRNA transcription or CAG-expanded HTT protein expression in a cell, comprising contacting the cell with an effective amount of an oligomer targeting a differentiating polymorphism, wherein the differentiating polymorphism is selected from rs72239206, rs363107, rs362313, rs2530595, rs113407847. Specific oligomer sequences are also provided.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Patent Application Ser. Nos. 62/052,282 filed on 18 Sep. 2014 and 62/191,144 filed on 10 Jul. 2015, both entitled “ALLELE-SPECIFIC THERAPY FOR HUNTINGTON DISEASE HAPLOTYPES”.

FIELD OF INVENTION

The present invention relates to methods and compositions for the treatment of Huntington's disease (HD) by allele-specific HTT silencing suitable for the majority of HD patients, via haplotype-specific targeting of mutant HTT in these populations. The present invention further provides potent, selective silencing of the mutant transcript using nucleic acid silencing agents.

BACKGROUND

Huntington disease (HD, [MIM 143100]) is a monogenic movement disorder that is caused by an expanded CAG repeat in exon 1 of the Huntingtin gene (HTT) and is molecularly defined by more than 35 tandem CAG triplets in one copy of the HTT gene [1-3]. Expanded CAG triplets encode similarly repetitive glutamine residues in the HTT protein, leading to multiple downstream pathogenic effects and selective neuropathology [4]. The defined genetic cause of HD, and its consequent gain-of-function toxicity, allow for the suppression of HTT as a therapeutic strategy [5]. Multiple preclinical studies have shown reversal of HD phenotypes by inducible or exogenous silencing of transgenic mutant HTT [6-9]. However, reagents which silence both wild-type HTT and mutant HTT may have detrimental long-term consequences in humans. Constitutive loss of the murine homolog Hdh is embryonic lethal and postnatal repression of Hdh leads to neurodegenerative phenotypes, suggesting a crucial role for HTT in development and adulthood [10-13]. Wild-type HTT has also been shown to be protective against toxic effects of mutant HTT in a dose-dependent manner. The preferential silencing of mutant HTT, and preservation of normal wild-type HTT expression, may minimize loss-of-function effects and yield greater therapeutic benefit than total HTT suppression.

There are two classes of genetic targets which can be used to selectively suppress mutant HTT versus its normal counterpart: the expanded CAG repeat and polymorphisms linked with the pathogenic mutation [14]. The utility of both classes of targets is informed by genetic diversity at the HTT locus in a given patient population [15]. The CAG repeat is intrinsically polymorphic, and the ability to achieve pharmacological discrimination between expanded and normal CAG diminishes with decreasing size difference between the two repeats [16, 17]. In contrast, polymorphism—targeted or SNP-targeted silencing of mutant HTT has achieved potent reduction of mutant HTT with negligible effect on expression of normal HTT transcript by acting to degrade a mutant transcript bearing a specific target allele [18, 19]. Careful structure-activity studies of antisense oligonucleotides (ASOs) suggest that suppression of normal HTT may be avoided with SNP-targeted reagents given appropriate preclinical screens [19, 20].

A crucial question in the development of SNP-targeted reagents is the choice of allele target for maximum therapeutic benefit in the HD patient population. The time and cost of drug development requires clear prioritization of targets for allele-specific HTT silencing in the greatest proportion of patients. Heterozygosity of various target SNPs has been evaluated in local patient cohorts, but few phased estimates are available across diverse patient groups to guide development of allele-specific reagents. For example, the Δ2642 codon deletion present in exon 58 of HTT has been targeted for selective HTT silencing in vitro by siRNA [21], but the frequency of this polymorphism among HD chromosomes varies from 59% in an American cohort [22] to 18.6% in Italy [23]. No study has examined the phased heterozygosity and haplotype relationship of all potential targets, and it remains unclear which HTT polymorphism would offer treatment for the greatest number of patients worldwide.

SUMMARY

The present invention is based, in part, on the identification of polymorphisms associated with HD haplotypes, which may be targeted to preferentially silence the CAG-expanded mutant huntingtin gene. The present invention provides methods and compositions for the treatment of HD.

Provided herein is an efficient and useful panel of targets for allele-specific HTT silencing in the greatest number of HD patients of European ancestry to enable rational, haplotype-specific targeting of mutant HTT in these populations. In part, the present invention further provides potent, selective silencing of the mutant transcript using nucleic acid silencing agents.

In a first aspect, there is a method of reducing the expression of mutant HTT in a cell, including contacting the cell with an effective amount of a nucleic acid silencing agent that targets a specific HD haplotype.

In a further aspect of the invention, there is provided a method of selecting a nucleic acid silencing agent that targets a specific haplotype, including obtaining a nucleic acid sample from the subject; identifying one or more allele-specific polymorphisms in the nucleic acid sample; selecting a nucleic acid silencing agent comprising a sequence that preferentially targets the specific HD haplotype.

In a further aspect of the invention, there is provided a method of reducing the expression of mutant HTT in a subject, including obtaining a nucleic acid sample from the subject; identifying one or more than one allele-specific polymorphisms in the nucleic acid sample; selecting one or more than one nucleic acid silencing agents comprising a sequence that preferentially targets alleles on the specific HD haplotype; and administering to the subject an effective amount of the one or more than one nucleic acid silencing agent.

In a further aspect, there is provided an oligomer of between 10-30 nucleobases in length which includes a contiguous nucleotide sequence of a total of between 10-26 nucleotides, wherein the continuous nucleotide sequence is targeted to hybridize to a sequence selected from the group consisting of:

(SEQ ID NO: 522) 5′-TGACAGTTGTATTTTTGTTTGTGACACGTATTATCTGTTAAAACA TTTTC-3′; (SEQ ID NO: 523) 5′-TCTTAAACTTTTAAATGCCATTTGATCTTTGAAAATATATGTTTTA ATAGTGTATTTTAAG-3′; (SEQ ID NO: 524) 5′-CCCTCAGCGAGCAAGTCAAGCTCTTCACAGTGATGTCTTACA AGCGCAGAGGGCTCTGTGA-3′; (SEQ ID NO: 525) 5′-GCTTTGTCCCTCCCCCGCTTCCTCCCTCTGTGGGGAGGACCC GGGACCACAGCTGCTGGCC-3′; and (SEQ ID NO: 526) 5′-GGAGAGACTCCACTCTGAATGGGGCCGGGAGGTGGGGAGGA CTCCATTTCAGATGGGGTCG-3′; wherein the oligomer targets the bolded nucleotide(s), permits between 0-3 mismatches and reduces mutant Huntingtin (HTT) mRNA or mutant HTT protein in a cell or tissue.

In a further aspect, there is provided an oligomer of between 10-30 nucleobases in length and hybridizes to a sequence selected from the group consisting of:

(SEQ ID NO: 522) 5′-TGACAGTTGTATTTTTGTTTGTGACACGTATTATCTGTTAAAAC ATTTTC-3′; (SEQ ID NO: 523) 5′-TCTTAAACTTTTAAATGCCATTTGATCTTTGAAAATATATGTTTT AATAGTGTATTTTAAG-3′; (SEQ ID NO: 524) 5′-CCCTCAGCGAGCAAGTCAAGCTCTTCACAGTGATGTCTTACA AGCGCAGAGGGCTCTGTGA-3′; (SEQ ID NO: 525) 5′-GCTTTGTCCCTCCCCCGCTTCCTCCCTCTGTGGGGAGGACC CGGGACCACAGCTGCTGGCC-3′; and (SEQ ID NO: 526) 5′-GGAGAGACTCCACTCTGAATGGGGCCGGGAGGTGGGGAGG ACTCCATTTCAGATGGGGTCG-3′; wherein the oligomer targets the bolded nucleotide(s), and reduces mutant Huntingtin (HTT) mRNA or mutant HTT protein in a cell or tissue.

In a further aspect, there is provided an oligomer of between 10-30 nucleobases in length and hybridizes to a sequence selected from the group consisting of:

(SEQ ID NO: 522) 5′-TGACAGTTGTATTTTTGTTTGTGACACGTATTATCTGTTAAAAC ATTTTC-3′; (SEQ ID NO: 523) 5′-TCTTAAACTTTTAAATGCCATTTGATCTTTGAAAATATATGTTTT AATAGTGTATTTTAAG-3′; (SEQ ID NO: 524) 5′-CCCTCAGCGAGCAAGTCAAGCTCTTCACAGTGATGTCTTACA AGCGCAGAGGGCTCTGTGA-3′; (SEQ ID NO: 525) 5′-GCTTTGTCCCTCCCCCGCTTCCTCCCTCTGTGGGGAGGACC CGGGACCACAGCTGCTGGCC-3′; and (SEQ ID NO: 526) 5′-GGAGAGACTCCACTCTGAATGGGGCCGGGAGGTGGGGAGG ACTCCATTTCAGATGGGGTCG-3′; wherein the oligomer targets the bolded nucleotide(s).

In a further aspect, there is provided an oligomer of between 10-30 nucleobases in length and hybridizes to a sequence selected from the group consisting of:

(SEQ ID NO: 522) 5′-TGACAGTTGTATTTTTGTTTGTGACACGTATTATCTGTTAA AACATTTTC-3′; (SEQ ID NO: 523) 5′-TCTTAAACTTTTAAATGCCATTTGATCTTTGAAAATATATGTT TTAATAGTGTATTTTAAG-3′; (SEQ ID NO: 524) 5′-CCCTCAGCGAGCAAGTCAAGCTCTTCACAGTGATGTCTTAC AAGCGCAGAGGGCTCTGTGA-3′; (SEQ ID NO: 525) 5′-GCTTTGTCCCTCCCCCGCTTCCTCCCTCTGTGGGGAGGAC CCGGGACCACAGCTGCTGGCC-3′; and (SEQ ID NO: 526) 5′-GGAGAGACTCCACTCTGAATGGGGCCGGGAGGTGGGGAGG ACTCCATTTCAGATGGGGTCG-3′; wherein the oligomer reduces mutant Huntingtin (HTT) mRNA or mutant HTT protein in a cell or tissue.

In a further aspect, there is provided a pharmaceutical composition including the oligomer described herein and a pharmaceutically acceptable diluent, carrier, salt or adjuvant.

In a further aspect, there is provided a method of reducing mutant Huntingtin (HTT) mRNA or mutant HTT protein in a cell or tissue, including contacting the cell or tissue with an effective amount of an oligomer targeting a differentiating polymorphism, wherein the differentiating polymorphism is selected from rs72239206, rs363107, rs362313, rs2530595, rs113407847.

In a further aspect, there is provided a method of reducing mutant Huntingtin (HTT) mRNA or mutant HTT protein in a cell or tissue, including contacting the cell or tissue with an effective amount of an oligomer described herein or a pharmaceutical composition described herein.

In a further aspect, there is provided a method of treating Huntington Disease (HD) in a mammal, including administering to the mammal an effective amount of an oligomer targeting a differentiating polymorphism, wherein the differentiating polymorphism is selected from rs72239206, rs363107, rs362313, rs2530595, rs113407847.

In a further aspect, there is provided a method of treating a Huntington Disease (HD) in a mammal, comprising administering to the mammal an effective amount of an oligomer described herein; or a pharmaceutical composition described herein; wherein the mammal is currently suffering from or at risk of suffering from HD.

In a further aspect, there is provided a use of an oligomer described herein in the preparation of a medicament for the treatment of HD.

In a further aspect, there is provided a use of an oligomer for the treatment of HD, wherein the oligomer targets a differentiating polymorphism, wherein the differentiating polymorphism is selected from rs72239206, rs363107, rs362313, rs2530595, rs113407847.

In a further aspect, there is provided a use of an oligomer described herein for the treatment of HD.

In a further aspect, there is provided a use of a pharmaceutical composition described herein for the treatment of HD.

In a further aspect, there is provided an oligomer described herein for use in the treatment of HD.

In a further aspect, there is provided a commercial package, comprising: an oligomer described herein; and instructions for the treatment of HD.

In a further aspect, there is provided an oligomer wherein the oligomer is selected from the group consisting of:

5′-G*A*T*A*A*t*a*c*g*t*g*t*c*a*C*A*A*A*C-3′; 5′-A*T*A*A*T*a*c*g*t*g*t*c*A*C*A*A*A-3′; 5′-T*A*A*T*a*c*g*t*g*t*c*A*C*A*A-3′; 5′-A*T*A*A*t*a*c*g*t*g*t*c*a*C*A*A*A-3′; 5′-T*A*T*A*t*t*t*t*c*a*a*a*g*A*T*C*A-3′; 5′-A*A*G*A*c*a*t*c*a*c*t*g*t*G*A*A*G-3′ 5′-T*C*C*T*c*c*c*c*a*c*a*g*a*G*G*G*A-3′; and 5′-C*T*C*C*c*c*a*c*c*t*c*c*c*G*G*C*C-3′. wherein capital letters represent LNA monomers, lower case letters represent DNA monomers and “*” represents a phosphorothioate linkage group between the monomers.

In a further aspect, there is provided a oligomer having a sequence selected from the group consisting of:

(SEQ ID NO: 36) 5′-GATAATACGTGTCACAAAC-3′; 1 (SEQ ID NO: 66) 5′-ATAATACGTGTCACAAA-3′; (SEQ ID NO: 92) 5′-TAATACGTGTCACAA-3′; (SEQ ID NO: 163) 5′-TATATTTTCAAAGATCA-3′; (SEQ ID NO: 268) 5′-AAGACATCACTGTGAAG-3′; (SEQ ID NO: 373) 5′-TCCTCCCCACAGAGGGA-3′; and (SEQ ID NO: 478) 5′-CTCCCCACCTCCCGGCC-3′; wherein the oligomer reduces mutant Huntingtin (HTT) mRNA or mutant HTT protein in a cell or tissue.

The HD haplotype may be the A1, A2 or the A3a haplotype. The allele-specific polymorphism may be selected from the group consisting of rs72239206, rs363107, rs362313, rs2530595 or rs113407847.

The oligomer may be an antisense oligonucleotide. The oligomer may be selected from the group comprising SEQ ID NO: 6-517 or a fragment thereof. The oligomer may be 10 to 30, 10 to 14, 12 to 25, 15 to 25, or 18 to 24 nucleotides in length. The subject or patient may have a European or Caucasian marker as described herein.

The oligomer may be selected from SEQ ID NOs: 6-10. The oligomer may be selected from SEQ ID NOs: 11-517. The oligomer may have a sequence selected from the group consisting of:

(SEQ ID NO: 36) 5′-GATAATACGTGTCACAAAC-3′; (SEQ ID NO: 66) 5′-ATAATACGTGTCACAAA-3′; (SEQ ID NO: 92) 5′-TAATACGTGTCACAA-3′; (SEQ ID NO: 163) 5′-TATATTTTCAAAGATCA-3′; (SEQ ID NO: 268) 5′-AAGACATCACTGTGAAG-3′; (SEQ ID NO: 373) 5′-TCCTCCCCACAGAGGGA-3′; and (SEQ ID NO: 478) 5′-CTCCCCACCTCCCGGCC-3′.

The oligomer may include nucleotide analogues. The oligomer may include a modified internucleoside linkage. The modified internucleoside linkage may be a peptide-nucleic acid linkage, a morpholino linkage, a N3′ to P5′ phosphoramidate linkage, a methylphosphonate linkage or a phosphorothioate linkage. The oligomer may have one or more modified sugar moieties. The modified sugar moiety may be 2′-O-alkyl oligoribonucleotide. The oligomer may be a gapmer. The oligomer may have a 2′MOE gapmer modification. The oligomer may have a modified nucleobase. The modified nucleobase may be a 5-methyl pyrimidine or a 5-propynyl pyrimidine. The one or more nucleotide analogues may include a locked nucleic acid (LNA). The LNA units include beta-D-oxy-LNA monomers. The cell may be within a tissue of a mammal. The mammal may be a human.

The ASO may further include a modified internucleoside linkage. The modified internucleoside linkage may be a peptide-nucleic acid linkage, a morpholino linkage, a N3′ to P5′ phosphoramidate linkage, a methylphosphonate linkage or a phosphorothioate linkage. The ASO may further include a modified sugar moiety. The modified sugar moiety may be a 2′-O-alkyl oligoribonucleotide. The ASO may further have a 2′MOE gapmer modification. The ASO may further have a 2′OMe gapmer modification. The ASO may further include a modified nucleobase. The modified nucleobase may be a 5-methyl pyrimidine or a 5-propynyl pyrimidine.

This summary of the invention does not necessarily describe all features of the invention. Other aspects, features and advantages of the present invention will become apparent to those of ordinary skill in the art upon review of the following description of specific embodiments of the invention.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1(a) The most common HD haplotype, A1, is uniquely defined by three transcribed polymorphisms in high pairwise linkage disequilibrium across HTT. The 4 bp indel rs72239206 represents a novel polymorphism associated with the CAG expansion. (b) The second most common HD haplotype, A2, is defined by five intragenic SNPs. Three of these polymorphisms (rs363107, rs362313, and rs2530595) represent novel HD-associated polymorphisms. (c) HD-associated A3a, the third most common HD haplotype, is specifically marked by the novel SNP rs113407847. Right panels in (a) and (b) show pairwise LD plot (r²) of A1 and A2 haplotype-defining polymorphisms as calculated from 700 phased haplotypes of European Caucasians.

FIG. 2(a) Passive transfection of patient-derived lymphoblasts with ΔACTT-complementary ASO selectively reduces mutant HTT protein. Patient lymphoblasts transfected with 5-7-5 (SEQ ID NO: 66) and 5-9-5(SEQ ID NO: 36) LNA gapmers show dose-dependent reduction of mutant HTT protein relative to untreated controls. Non-muscle myosin was used as a loading control. (b) Quantification of relative mHTT and wtHTT levels following 120 hr treatment of juvenile A1 lymphoblasts at 78, 312, and 1250 nM ASO in media (n=4, *p<0.05).

FIG. 3(a) Design of antisense oligonucleotide gapmers selectively targeting mutant HTT A1 mRNA at the ΔACTT (rs72239206) sequence. (b) Transfection of patient-derived lymphoblasts (44/18 CAG) with ΔACTT-complementary ASOs selectively reduces mutant HTT mRNA. Patient lymphoblasts transfected with 5-9-5 (SEQ ID NO: 36), 5-7-5 (SEQ ID NO: 66) and 4-7-4 LNA (SEQ ID NO: 92) gapmers show dose-dependent reduction of mutant HTT mRNA relative to untreated controls, falling to 21.5% mutant HTT mRNA at the highest 4-7-4 dose. Wild-type HTT mRNA levels do not fall below untreated levels at any tested dose of 5-7-5 (SEQ ID NO: 66) or 4-7-4 LNA (SEQ ID NO: 92) gapmer. (c) Dose-dependent reduction of mutant HTT protein relative to untreated controls, sparing wtHTT at all tested 5-7-5 and 4-7-4 LNA gapmer doses. **and*** represent p=0.01 and p=0.001 by ANOVA with Bonferroni post hoc.

FIG. 4(a) Four weeks post ICV injection of YAC128 mice with WT 5-9-5 LNA gapmer complementary to the rs72239206 major allele results in potent reduction of mutant HTT protein in vivo relative to untreated controls. (b) Quantification of relative human HTT and mouse Htt levels following treatment with the indicated doses of WT 5-9-5 LNA gapmer.

FIG. 5 shows that active transfection of patient-derived lymphoblasts with rs72239206-complementary ASO selectively reduces mutant HTT protein. HD patient-derived lymphoblasts (A1/C haplotypes; CAG lengths 59/18) treated with a 4-9-4 LNA/phosphorothioate backbone gapmer with sequence +A*+T*+A*+A*T*A*C*G*T*G*T*C*A*+C*+A*+A*+A (*=phosphorothioate linkages, +=LNA) (SEQ ID NO: 66) show a dose-dependent reduction of mutant HTT protein relative to untreated controls. Cells were treated with either 0.5, 1, 2 or 5 μM of ASO or left untreated for 120 hrs and harvested for western blot analysis. Mutant and wild type huntingtin were separated on a 7% low-bis gel and band intensities were quantified by densitometry. Non-muscle myosin was used a loading/normalization control. Relative huntingtin levels are presented on the graph. N=4, error bars represent standard error.

FIG. 6 shows that active transfection of patient-derived lymphoblasts with a rs2530595-complementary ASO reduces mutant HTT protein. HD patient-derived lymphoblasts (A2/C haplotypes; CAG lengths 44/18) treated with a 4-9-4 LNA/phosphorothioate backbone gapmer with the sequence +T*+C*+C*+T*C*C*C*C*A*C*A*G*A*+G*+G*+G*+A (*=phosphorothioate linkages, +=LNA) (SEQ ID NO: 373) show a dose-dependent reduction of mutant HTT protein relative to untreated controls. Cells were treated with either 0.5, 1, 2 or 5 μM of ASO or left untreated for 120 hrs and harvested for western blot analysis. Mutant and wild type huntingtin were separated on a 7% low-bis gel and band intensities were quantified by densitometry. Non-muscle myosin was used a loading/normalization control. Relative huntingtin levels are presented on the graph below. N=3, error bars represent standard error.

FIG. 7 shows that active transfection of patient-derived lymphoblasts with a rs363107-complementary ASO reduces mutant HTT protein. HD patient-derived lymphoblasts (A2/C haplotypes; CAG lengths 44/18) treated with a 4-9-4 LNA/phosphorothioate backbone gapmer with sequence +T*+A*+T*+A*T*T*T*T*C*A*A*A*G*+A*+T*+C*+A (*=phosphorothioate linkages, +=LNA) (SEQ ID NO: 163) show a dose-dependent reduction of mutant HTT protein relative to untreated controls. Cells were treated with either 0.5, 1, 2 or 5 μM of ASO or left untreated for 120 hrs and harvested for western blot analysis. Mutant and wild type huntingtin were separated on a 7% low-bis gel and band intensities were quantified by densitometry. Non-muscle myosin was used a loading/normalization control. Relative huntingtin levels are presented on the graph below. N=3, error bars represent standard error.

FIG. 8 shows that active transfection of patient-derived lymphoblasts with a rs362313-complementary ASO reduces mutant HTT protein. HD patient-derived lymphoblasts (A2/C haplotypes; CAG lengths 44/18) treated with a 4-9-4 LNA/phosphorothioate backbone gapmer with the sequence +A*+A*+G*+A*C*A*T*C*A*C*T*G*T*+G*+A*+A*+G (*=phosphorothioate linkages, +=LNA) (SEQ ID NO: 268) show a dose-dependent reduction of mutant HTT protein relative to untreated controls. Cells were treated with either 0.5, 1, 2 or 5 μM of ASO or left untreated for 120 hrs and harvested for western blot analysis. Mutant and wild type huntingtin were separated on a 7% low-bis gel and band intensities were quantified by densitometry. Non-muscle myosin was used a loading/normalization control. Relative huntingtin levels are presented on the graph below. N=4, error bars represent standard error.

FIG. 9 shows that active transfection of patient-derived lymphoblasts with a rs113407847-complementary ASO reduces mutant HTT protein. HD patient-derived lymphoblasts (A3a/C haplotypes; CAG lengths 67/15) treated with a 4-9-4 LNA/phosphorothioate backbone gapmer with the sequence +C*+T*+C*+C*C*C*A*C*C*T*C*C*C*+G*+G*+C*+C (*=phosphorothioate linkages, +=LNA) (SEQ ID NO: 478) show a dose-dependent reduction of mutant HTT protein relative to untreated controls. Cells were treated with either 0.5, 1, 2 or 5 μM of ASO or left untreated for 120 hrs and harvested for western blot analysis. Mutant and wild type huntingtin were separated on a 7% low-bis gel and band intensities were quantified by densitometry. Non-muscle myosin was used a loading/normalization control. Relative huntingtin levels are presented on the graph below. N=4, error bars represent standard error.

DETAILED DESCRIPTION

The invention provides, in part, methods and compositions for the treatment of HD. More particularly, polymorphisms are provided that define specific HD haplotypes; such polymorphisms constitute optimal targets for development of allele-specific silencing compounds for use in the treatment, prevention or amelioration of HD.

In the description that follows, a number of terms are used extensively, the following definitions are provided to facilitate understanding of various aspects of the invention. Use of examples in the specification, including examples of terms, is for illustrative purposes only and is not intended to limit the scope and meaning of the embodiments of the invention herein.

Any terms not directly defined herein shall be understood to have the meanings commonly associated with them as understood within the present field of art. Certain terms are discussed below, or elsewhere in the specification, to provide additional guidance to the practitioner in describing the compositions, devices, methods and the like of embodiments, and how to make or use them. It will be appreciated that the same thing may be said in more than one way. Consequently, alternative language and synonyms may be used for any one or more of the terms discussed herein. No significance is to be placed upon whether or not a term is elaborated or discussed herein. Some synonyms or substitutable methods, materials and the like are provided. Recital of one or a few synonyms or equivalents does not exclude use of other synonyms or equivalents, unless it is explicitly stated. Use of examples in the specification, including examples of terms, is for illustrative purposes only and does not limit the scope and meaning of the embodiments described herein.

A method is provided for “treating” Huntington's Disease (HD), wherein treating is meant to encompass selective silencing of CAG-expanded Huntingtin gene (HTT) transcripts and ameliorating symptoms associated with HD, while sparing wild type HTT. The term “treating” as used herein is also meant to include the administration at any stage of HD, including early administration of a compound or late administration. A person of skill in the art would appreciate that the term “ameliorating” is meant to include the prospect of making the HD more tolerable for a subject afflicted therewith (for example, by improving movement and delaying death). Accordingly, as used herein “treatment” may refer to the prevention of HD, the amelioration of symptoms associated with HD, improving movement or other symptoms in the HD patient, extending the life expectancy of the HD patient, or combinations thereof.

Antisense oligonucleotide compounds are typically single stranded DNA or RNA compounds which bind to complementary RNA compounds, such as target mRNA molecules or precursor mRNA molecules, and catalyze downstream events, including inducing RNAse H-dependent degradation of transcripts (Bennett and Swayze 2010). This process is usually passive, in that it does not require or involve additional enzymes to mediate the RNA interference process. Specific targeting of antisense compounds to inhibit the expression of a desired gene may generally involve designing the antisense compound to have a homologous, complementary sequence to the desired gene transcript. Perfect homology may not be necessary for the RNA interference effect. In one embodiment of the invention, the antisense compounds include any DNA or RNA compound with sufficient complementary homology to preferentially bind to the CAG-expanded repeat HTT precursor mRNA or mRNA transcript causing degradation of the CAG-expanded repeat huntingtin transcripts and resulting in reduced production of the polyglutamine expanded repeat huntingtin proteins.

The antisense compounds may be modified to enhance the stability of the oligonucleotides, particularly for in vivo use. Numerous examples of methods for designing and optimizing antisense compounds are found in the journal literature—i.e. (Pan and Clawson 2006; Patzel 2007; Peek and Behlke 2007). The present inventors provide non-limiting examples of antisense compounds which modulate the expression of CAG-expanded huntingtin genes.

Antisense oligonucleotide (ASO) sequences as described herein or for use as described herein may be administered by means of a medical device or appliance such as an implant, graft, prosthesis, stent, etc. Also, implants may be devised which are intended to contain and release such compounds or compositions. An example would be an implant made of a polymeric material adapted to release the compound over a period of time.

“Oligomer” as used herein is meant to encompass any nucleic acid silencing agent (for example, siRNa, miRNA, ASO in all of their modified forms as described herein) and compositions comprising the nucleic acid silencing agent. An oligomer may act by hybridizing to a target sequence.

A phosphorothioate oligonucleotide bond modification alters the phosphate linkage by replacing one of the non-bridging oxygens with sulfur. The introduction of phosphorothioate linkages alters the chemical properties of the oligonucleotide. In particular, the addition of phosphorothioate linkages reduces nuclease degradation of the oligonucleotide, thereby increasing the half-life in situ. Accordingly, this modification is particularly useful for antisense oligonucleotides, which when introduced into cells or biological matrices can interact with target nucleic acids to silence the expression of a particular transcript. Oligonucleotides containing phosphorothioate linkages accomplish this feat either through direct blockage of translation or enabling enzymatic degradation of the target transcript (for example, via RNase H).

Although phosphorothioate linkages provide improved half-life, the introduction of these linkages into an oligonucleotide may also introduce limitations to their function as antisense oligonucleotides. Each phosphorothioate linkage creates a chiral center at each bond, which may result in multiple isomers of the oligonucleotide generated during synthesis and the isomers may have differential characteristics and functional properties. However, much of the isomer effects may be mitigated through careful positioning of the modifications or by using additional modifications in conjunction with the phosphorothioate bonds.

One or more of the phosphodiester linkages of the oligonucleotide moiety may be modified by replacing one or both of the two bridging oxygen atoms of the linkage with analogues such as —NH, —CH2, or —S. Other oxygen analogues known in the art may also be used.

A “modified oligonucleotide” as used herein is meant to include oligonucleotides that are substituted or modified. In addition to the naturally occurring primary bases adenine, guanine, cytosine, and thymine, or other natural bases such as inosine, deoxyinosine, and hypoxanthine, there are numerous other modifications. For example, isosteric purine 2′ deoxy-furanoside analogues, 2′-deoxynebularine or 2′ deoxyxanthosine, or other purine and pyrimidine analogues such as 5-methyl pyrimidine or a 5-propynyl pyrimidine may also be utilized to improve stability and target hybridization.

A “modified sugar” as used herein when discussing an oligonucleotide moiety, a sugar modified or replaced so as to be ribose, glucose, sucrose, or galactose, or any other sugar. Alternatively, the oligonucleotide may have one or more of its sugars substituted or modified in its 2′ position, i.e. 2′ alkyl or 2′-o-alkyl. An example of a 2′-O-alkyl sugar is a 2′-O-methylribonucleotide. Furthermore, the oligonucleotide may have one or more of its sugars substituted or modified to form an a-anomeric sugar.

“Second-generation” oligonucleotides as used herein may be defined as oligonucleotides that are resistant to degradation by cellular nucleases and capable of hybridizing specifically to their target precursor mRNA or mRNA with equal or higher affinity than first generation ASOs. An example of a 2^(nd) generation ASO is a 2′-O-(2-Methoxyethyl)-RNA (2′MOE gapmer modification). With a 2′-MOE or a 2′OMe gapmer the 5′ and 3′ ends may have 2′-MOE modified nucleotides to protect against degradation, but the gap between the 5′ and 3′ ends may be unmodified phosphodiester or phosphorothioate linkages that are substrates for RNase H. Numerous other chemical modifications have been developed to improve ASOs. For example, morpholino, N3′ to P5′ phosphoramidate, and methylphosphonate chemical modifications are known in the art (N. Dias, and C. A. Stein 2002). Furthermore, peptide nucleic acids (PNAs) may also be used.

“LNA” as used herein refers to a Locked Nucleic Acid, which is an RNA analog in which the ribose ring is connected by a methylene bridge between the 2′-O and 4′-C atoms thus “locking” the ribose ring in the ideal conformation for Watson-Crick binding. When incorporated into a DNA or RNA oligonucleotide LNAs make the pairing with a complementary nucleotide strand more rapid and increases the stability of the resulting duplex. LNA oligonucleotides have better thermal stability when hybridized to a complementary DNA or RNA strand. Furthermore, LNA oligonucleotides may be made shorter than traditional DNA or RNA oligonucleotides. LNA oligonucleotides are especially useful to detect small or highly similar targets.

“Gapmer” or “gap oligomer”, as used herein, refers to a chimeric oligomer having a central portion (a “gap”) flanked by 3′ and 5′ “wings”, wherein the gap has a modification that is different as compared to each of the wings. Such modifications may include nucleobase, monomeric linkage, and sugar modifications as well as the absence of a modification (such as unmodified RNA or DNA). Accordingly, a gapmer may be as simple as RNA wings separated by a DNA gap. In some cases, the nucleotide linkages in the wings may be different than the nucleotide linkages in the gap. In certain embodiments, each wing comprises nucleotides with high affinity modifications and the gap comprises nucleotides that do not comprise that modification. Alternatively, the nucleotides in the gap and the nucleotides in the wings may have high affinity modifications, but the high affinity modifications in the gap are different than the high affinity modifications in each of the wings. The modifications in the wings may confer resistance to cleavage by endogenous nucleases, including RNaseH, while the modifications in the gap may be substrates for RNase H. The modifications in the wings may confer resistance to cleavage by endogenous nucleases, including RNaseH, while the modifications in the gap may be substrates for RNase H. The modifications in the wings may be the same or different from one another. The nucleotides in the gap may be unmodified and nucleotides in the wings may be modified. A gapmer has a wing-gap-wing ratio, which may be represented numerically (wing#-gap#-wing#). The gapmer may be symmetric (for example, 9-13-9, 9-12-9, 9-11-9, 9-10-9, 9-9-9, 9-8-9, 9-7-9, 9-6-9, 9-5-9, 9-4-9, 9-3-9, 9-2-9, 9-1-9, 8-15-8, 8-14-8, 8-13-8, 8-12-8,8-11-8, 8-10-8, 8-9-8, 8-8-8, 8-7-8, 8-6-8, 8-5-8, 8-4-8, 8-3-8, 8-2-8, 8-1-8, 7-15-7, 7-14-7, 7-13-7, 7-12-7, 7-11-7, 7-10-7, 7-9-7, 7-8- 7, 7-7-7, 7-6-7, 7-5-7, 7-4-7, 7-3-7, 7-2-7, 7-1-7, 6-15-6, 6-14-6, 6-13-6, 6-12-6, 6-11-6, 6-10-6, 6-9-6, 6-8- 6, 6-7-6, 6-6-6, 6-5-6, 6-4-6, 6-3-6, 6-2-6, 6-1-6, 5-15-5, 5-14-5, 5-13-5, 5-12-5, 5-11-5, 5-10-5, 5-9-5, 5- 8-5, 5-7-5, 5-6-5, 5-5-5, 5-4-5, 5-3-5, 5-2-5, 5-1-5, 4-17-4, 4-16-4, 4-15-4, 4-14-4, 4-13-4, 4-12-4, 4-11-4, 4-10-4, 4-9-4, 4-8-4, 4-7-4, 4-6-4, 4-5-4, 4-4-4, 4-3-4, 3-24-3, 3-23-3, 3-22-3, 3-21-3, 3-20-3, 3-19-3, 3-18- 3, 3-17-3, 3-16-3, 3-15-3, 3-14-3, 3-13-3, 3-12-3, 3-11-3, 3-10-3, 3-9-3, 3-8-3, 3-7-3, 3-6-3, 3-5-3, 3-4-3, 2-26-2, 2-25-2, 2-24-2, 2-22-2, 2-21-2, 2-20-2, 2-19-2, 2-18-2, 2-17-2, 2-16-2, 2-15-2, 2-14-2, 2-13-2, 2-12-2, 2-11-2, 2-10-2, 2-9-2, 2-8-2, 2-7-2, 2-6-2, 2-5-2, 1-26-1, 1-25-1, 1-24-1, 1-22-1, 1-21-1, 1-20-1, 1-19-1, 1-18-1, 1-17-1, 1-16-1, 1-15-1, 1-14-1, 1-13-1, 1-12-1, 1-11-1, 1-10-1, 1-9-1, 1-8-1 or 1-7-1). The gapmer may be asymmetric (for example, 8-13-9, 8-12-9, 8-11-9, 8-10-9, 8-9-9, 8-8-9, 8-7-9, 8-6-9, 8-5-9, 8-4-9, 8-3-9, 8-2-9, 8-1-9, 7-15-8, 7-14-8, 7-13-8, 7-12-8, 7-11-8, 7-10-8, 7-9-8, 7-8-8, 7-7-8, 7-6-8, 7-5-8, 7-4-8, 7-3-8, 7-2-8, 7-1-8, 6-15-7, 6-14-7, 6-13-7, 6-12-7, 6-11-7, 6-10-7, 6-9-7, 6-8-7, 6-7-7, 6-6-7, 6-5- 7, 6-4-7, 6-3-7, 6-2-7, 6-1-7, 5-15-6, 5-14-6, 5-13-6, 5-12-6, 5-11-6, 5-10-6, 5-9-6, 5-8-6, 5-7-6, 5-6-6, 5-5- 6, 5-4-6, 5-3-6, 5-2-6, 5-1-6, 4-15-5, 4-14-5, 4-13-5, 4-12-5, 4-11-5, 4-10-5, 4-9-5, 4-8-5, 4-7-5, 4-6-5, 4- 5-5, 4-4-5, 4-3-5, 4-2-5, 4-1-5, 3-17-4, 3-16-4, 3-15-4, 3-14-4, 3-13-4, 3-12-4, 3-11-4, 3-10-4, 3-9-4, 3-8-4, 3-7-4, 3-6-4, 3-5-4, 3-4-4, 3-3-4, 2-24-3, 2-23-3, 2-22-3, 2-21-3, 2-20-3, 2-19-3, 2-18-3, 2-17-3, 2-16-3, 2-15-3, 2-14-3, 2-13-3, 2-12-3, 2-11-3, 2-10-3, 2-9-3, 2-8-3, 2-7-3, 2-6-3, 2-5-3, 2-4-3, 1-26-2, 1-25-2, 1-24-2, 1-22-2, 1-21-2, 1-20-2, 1-19-2, 1-18-2, 1-17-2, 1-16-2, 1-15-2, 1-14-2, 1-13-2, 1-12-2, 1-11-2, 1-10-2, 1-9-2, 1-8-2, 1-7-2, 3-26-1, 3-25-1, 3-24-1, 3-22-1, 3-21-1, 3-20-1, 3-19-1, 3-18-1, 3-17-1, 3-16-1, 3-15-1, 3-14-1, 4-13-1, 4-12-1, 4-11-1, 4-10-1, 3-9-1, 3-8-1 or 4-7-1).

A chimeric antisense oligonucleotide with a deoxy gap region which is greater than 10 nucleotides in length may be referred as a “gap-widened antisense oligonucleotide”. The wing regions may be one to eight high-affinity modified nucleotides in length. The gap-widened antisense oligonucleotides may be 12 to 30 nucleotides in length capable of having, for example, various wing-gap-wing ratio may be selected from: 2-15-1, 1-15-2, 1-14-3, 3-14-1, 1-13-4, 4-13-1, 2-13-3, 3-13-2, 1-12-5, 5-12-1, 2-12-4, 4-12-2, 3-12-3, 1-11-6, 6-11-1, 2-11-5, 5-11-2, 3-11-4, 4-11-3, 2-16-1, 1-16-2, 1-15-3, 3-15-1, 2-15-2, 1-14-4, 4-14-1, 2-14-3, 3-14-2, 1-13-5, 5-13-1, 2-13-4, 4-13-2, 3-13-3, 1-12-6, 6-12-1, 2-12-5, 5-12-2, 3-12-4, 4-12-3, 1-11-7, 7-11-1, 2-11-6, 6-11-2, 3-11-5, 5-11-3, 4-11-4, 1-18-1, 1-17-2, 2-17-1, 1-16-3, 1-16-3, 2-16-2, 1-15-4, 4-15-1, 2-15-3, 3-15-2, 1-14-5, 5-14-1, 2-14-4, 4-14-2, 3-14-3, 1-13-6, 6-13-1, 2-13-5, 5-13-2, 3-13-4, 4-13-3, 1-12-7, 7-12-1, 2-12-6, 6-12-2, 3-12-5, 5-12-3, 4-12-4, 1-11-8, 8-11-1, 2-11-7, 7-11-2, 3-11-6, 6-11-3, 4-11-5, 5-11-4, 1-18-1, 1-17-2, 2-17-1, 1-16-3, 3-16-1, 2-16-2, 1-15-4, 4-15-1, 2-15-3, 3-15-2, 1-14-5, 2-14-4, 4-14-2, 3-14-3, 1-13-6, 6-13-1, 2-13-5, 5-13-2, 3-13-4, 4-13-3, 1-12-7, 7-12-1, 2-12-6, 6-12-2, 3-12-5, 5-12-3, 4-12-4, 1-11-8, 8-11-1, 2-11-7, 7-11-2, 3-11-6, 6-11-3, 4-11-5, 5-11-4, 1-19-1, 1-18-2, 2-18-1, 1-17-3, 3-17-1, 2-17-2, 1-16-4, 4-16-1, 2-16-3, 3-16-2, 1-15-5, 2-15-4, 4-15-2, 3-15-3, 1-14-6, 6-14-1, 2-14-5, 5-14-2, 3-14-4, 4-14-3, 1-13-7, 7-13-1, 2-13-6, 6-13-2, 3-13-5, 5-13-3, 4-13-4, 1-12-8, 8-12-1, 2-12-7, 7-12-2, 3-12-6, 6-12-3, 4-12-5, 5-12-4, 2-11-8, 8-11-2, 3-11-7, 7-11-3, 4-11-6, 6-11-4, 5-11-5, 1-20-1, 1-19-2, 2-19-1, 1-18-3, 3-18-1, 2-18-2, 1-17-4, 4-17-1, 2-17-3, 3-17-2, 1-16-5, 2-16-4, 4-16-2, 3-16-3, 1-15-6, 6-15-1, 2-15-5, 5-15-2, 3-15-4, 4-15-3, 1-14-7, 7-14-1, 2-14-6, 6-14-2, 3-14-5, 5-14-3, 4-14-4, 1-13-8, 8-13-1, 2-13-7, 7-13-2, 3-13-6, 6-13-3, 4-13-5, 5-13-4, 2-12-8, 8-12-2, 3-12-7, 7-12-3, 4-12-6, 6-12-4, 5-12-5, 3-11-8, 8-11-3, 4-11-7, 7-11-4, 5-11-6, 6-11-5, 1-21-1, 1-20-2, 2-20-1, 1-20-3, 3-19-1, 2-19-2, 1-18-4, 4-18-1, 2-18-3, 3-18-2, 1-17-5, 2-17-4, 4-17-2, 3-17-3, 1-16-6, 6-16-1, 2-16-5, 5-16-2, 3-16-4, 4-16-3, 1-15-7, 7-15-1, 2-15-6, 6-15-2, 3-15-5, 5-15-3, 4-15-4, 1-14-8, 8-14-1, 2-14-7, 7-14-2, 3-14-6, 6-14-3, 4-14-5, 5-14-4, 2-13-8, 8-13-2, 3-13-7, 7-13-3, 4-13-6, 6-13-4, 5-13-5, 1-12-10, 10-12-1, 2-12-9, 9-12-2, 3-12-8, 8-12-3, 4-12-7, 7-12-4, 5-12-6, 6-12-5, 4-11-8, 8-11-4, 5-11-7, 7-11-5, 6-11-6, 1-22-1, 1-21-2, 2-21-1, 1-21-3, 3-20-1, 2-20-2, 1-19-4, 4-19-1, 2-19-3, 3-19-2, 1-18-5, 2-18-4, 4-18-2, 3-18-3, 1-17-6, 6-17-1, 2-17-5, 5-17-2, 3-17-4, 4-17-3, 1-16-7, 7-16-1, 2-16-6, 6-16-2, 3-16-5, 5-16-3, 4-16-4,1-15-8, 8-15-1, 2-15-7, 7-15-2, 3-15-6, 6-15-3, 4-15-5, 5-15-4, 2-14-8, 8-14-2, 3-14-7, 7-14-3, 4-14-6, 6-14-4, 5-14-5, 3-13-8, 8-13-3, 4-13-7, 7-13-4, 5-13-6, 6-13-5, 4-12-8, 8-12-4, 5-12-7, 7-12-5, 6-12-6, 5-11-8, 8-11-5, 6-11-7, or 7-11-6. The gap-widened antisense oligonucleotides may have a 2-16-2, 3-14-3, or 4-12-4 wing-gap-wing ratio.

As used herein, the term “high-affinity modification” in relation to a nucleotide refers to a nucleotide having at least one modified nucleobase, internucleoside linkage or sugar moiety, such that the modification increases the affinity of an antisense compound comprising the modified nucleotide to a target nucleic acid. High-affinity modifications include, but are not limited to, bicyclic nucleic acid (BNA)s, LNAs and 2′-MOE. Furthermore, the desirable potency and toxicity characteristics may be obtained by selecting the nucleotide modifications, nucleotide analogues, modified inter-nucleoside linkages, including one or more modified sugar moieties and/or a gapmer wing-gap-wing ratio (for example, see US20100197762). The compounds, as described herein, may be in isolation, or may be linked to or in combination with tracer compounds, liposomes, carbohydrate carriers, polymeric carriers or other agents or excipients as will be apparent to one of skill in the art. In alternate embodiments, such compounds may further comprise an additional medicament, wherein such compounds may be present in a pharmacologically effective amount.

The term “medicament” as used herein refers to a composition that may be administered to a patient or test subject and is capable of producing an effect in the patient or test subject. The effect may be chemical, biological or physical, and the patient or test subject may be human, or a non-human animal, such as a rodent (for example, a transgenic mouse, a mouse or a rat), dog, cat, cow, sheep, horse, hamster, guinea pig, rabbit or pig. The medicament may be comprised of the effective chemical entity alone or in combination with a pharmaceutically acceptable excipient.

The term “pharmaceutically acceptable excipient” may include any and all solvents, dispersion media, coatings, antibacterial, antimicrobial or antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. An excipient may be suitable for intravenous, intraperitoneal, intramuscular, subcutaneous, intrathecal, topical or oral administration. An excipient may include sterile aqueous solutions or dispersions for extemporaneous preparation of sterile injectable solutions or dispersion. Use of such media for preparation of medicaments is known in the art.

Compositions or compounds according to some embodiments described herein may be administered in any of a variety of known routes. Examples of methods that may be suitable for the administration of a compound include oral, intravenous, intrathecal, inhalation, intramuscular, subcutaneous, topical, intraperitoneal, intra-rectal or intra-vaginal suppository, sublingual, and the like. The compounds described herein may be administered as a sterile aqueous solution, or may be administered in a fat-soluble excipient, or in another solution, suspension, patch, tablet or paste format as is appropriate. A composition comprising the compounds described herein may be formulated for administration by inhalation. For instance, a compound may be combined with an excipient to allow dispersion in an aerosol. Examples of inhalation formulations will be known to those skilled in the art. Other agents may be included in combination with the compounds described herein to aid uptake or metabolism, or delay dispersion within the host, such as in a controlled-release formulation. Examples of controlled release formulations will be known to those of skill in the art, and may include microencapsulation, embolism within a carbohydrate or polymer matrix, and the like. Other methods known in the art for making formulations are found in, for example, “Remington's Pharmaceutical Sciences”, (19th edition), ed. A. Gennaro, 1995, Mack Publishing Company, Easton, Pa.

The dosage of the compositions or compounds of some embodiments described herein may vary depending on the route of administration (oral, intravenous, intrathecal, inhalation, or the like) and the form in which the composition or compound is administered (solution, controlled release or the like). Determination of appropriate dosages is within the ability of one of skill in the art. As used herein, an “effective amount”, a “therapeutically effective amount”, or a “pharmacologically effective amount” of a compound refers to an amount of the antisense oligomer in such a concentration to result in a therapeutic level of the compound delivered over the term that the compound is used. This may be dependent on the mode of delivery, time period of the dosage, age, weight, general health, sex and diet of the subject receiving the compound. Methods of determining effective amounts are known in the art. It is understood that it may be desirable to target the compounds described herein to a desired tissue or cell type. The compounds described herein may thus be coupled to a targeting moiety. The compounds may be coupled to a cell uptake moiety. The targeting moiety may also function as the cell uptake moiety.

In general, antisense oligonucleotides as described herein may be used without causing substantial toxicity. Toxicity of the compounds as described herein can be determined using standard techniques, for example, by testing in cell cultures or experimental animals and determining the therapeutic index, i.e., the ratio between the LD50 (the dose lethal to 50% of the population) and the LD100 (the dose lethal to 100% of the population). In some circumstances however, such as in severe disease conditions, it may be appropriate to administer substantial excesses of the compositions. Some antisense oligonucleotides as described herein may be toxic at some concentrations. Titration studies may be used to determine toxic and non toxic concentrations. Toxicity may be evaluated by examining a particular antisense oligonucleotide's specificity across cell lines. Animal studies may be used to provide an indication if the compound has any effects on other tissues.

A “nucleic acid silencing agent” or an “agent” refers to a composition that acts in a sequence specific manner to effect a reduction in the level of a product (a “gene product”) of a given nucleic acid sequence (e.g. a ‘gene’). The reduction may be effected by interference with any of the processing of a pre-mRNA following transcription from the DNA of a cell or subject (e.g. splicing, 5′ capping, 5′ or 3′ processing, or export of the processed mRNA to the cytoplasm) or by interference with translation of a mature mRNA, or by specific, directed destruction of the pre-mRNA or mature mRNA. Antisense (ASO) and RNA interference (RNAi-effected by short interfering RNA, or siRNA) are two examples of such methods; microRNA (miRNA) is another.

An antisense oligonucleotide (ASO) is an oligonucleotide that is complementary to a specific RNA sequence, and when hybridized to this specific sequence, interferes with processing or translation of the RNA or triggers degradation of the specific RNA by enzymatic pathways (for example, RNAse H-dependent degradation). The nucleosides comprising an ASO may be purine or pyrimidine nucleosides, or a combination of purine and pyrimidine nucleosides, connected by an internucleoside linkage. ASOs are described generally in, for example, Crooke 2004. Annu. Rev. Med 55:61-95; and in Curr Mol Med 4:465-487. An siRNA is a short (20-30 nucleotide) double-stranded RNA (or modified RNA) molecule that may effect a reduction in the level of a gene product by allowing for specific destruction of mRNA via the RNA interference pathway. The specific mRNA is degraded in the cytoplasm by the RNA-induced silencing complex (RISC). An miRNA is a short (20-30 nucleotide) single-stranded RNA molecule that may effect a reduction in the level of a gene product. An miRNA is complementary to a part of an mRNA, either a coding region or a non-translated region (e.g. 5′ untranslated region (UTR), 3′ UTR). The miRNA may anneal to form a double-stranded complex and trigger degradation in a process similar to that of siRNA. Translation may also be disrupted by miRNA. A DNA ASO, commonly referred to simply as an ASO, is a short (12-50 nucleotide) single stranded DNA (or modified DNA) molecule that may effect a reduction in the level of a gene product by inducing specific destruction of pre-mRNA or mRNA via RNase H-mediated cleavage. The specific pre-mRNA or mRNA can be degraded in the nucleus and/or the cytoplasm by induction of RNAseH cleavage of DNA-RNA heteroduplexes. A DNA ASO, commonly referred to simply as an ASO, is a short (12-50 nucleotide) single stranded DNA (or modified DNA) molecule that may effect a reduction in the level of a gene product by inducing specific destruction of pre-mRNA or mRNA via RNase H-mediated cleavage. The specific pre-mRNA or mRNA can be degraded in the nucleus and/or the cytoplasm by induction of RNAseH cleavage of DNA-RNA heteroduplexes.

The term ‘nucleoside’ refers to a molecule of ribose or deoxyribose sugar bonded through carbon-1 of the sugar ring to a nitrogenous base. Examples of nitrogenous bases include purines such as adenine, guanine, 6-thioguanine, hypoxanthine, xanthine, and pyrimidines such as cytosine, thymine and uracil. Examples of purine nucleosides include adenosine (A), guanosine (G), inosine (I), 2′-O-methyl-inosine, 2′-O-methyl-adenosine, 2′-O-methyl-guanine, 2-chlorodeoxyadenosine, 7-halo-7-deaza-adenosine, 7-halo-7-deaza-guanine, 7-propyne-7-deaza adenosine, 7-propyne-7-deaza-guanine, 2-amino-adenosine, 7-deazainosine, 7-thia-7,9-dideazainosine, formycin B, 8-Azainosine, 9-deazainosine, allopurinol riboside, 8-bromo-inosine, 8-chloroinosine, 7-deaza-2-deoxy-xanthosine, 7-Deaza-8-aza-adenosine, 7-deaza-8-aza-guanosine, 7-deaza-8-aza-deoxyadenosine, 7-deaza-8-aza-deoxyguanosine, 7-deaza-adenosine, 7-deaza-guanosine, 7-deaza-deoxyadenosine, 7-deaza-deoxyguanosine, 8-amino-adenosine, 8-amino-deoxyadenosine, 8-amino-guanosine, 8-amino-deoxyguanosine,3-deaza-deoxyadenosine, 3-deaza-adenosine, 6-thio-deoxyguanosine, and the like, and other purine nucleosides as described in Freier et al 1997 (Nucleic Acids Res. 25:4429-4443), incorporated herein by reference. Examples of pyrimidine nucleosides include deoxyuridine (dU), uridine (U), cytidine (C), deoxycytidine (dC), thymidine (T), deoxythymidine (dT), 5-fluoro-uracil, 5-bromouracil, 2′-O-methyl-uridine, 2′-O-methyl cytidine, 5-iodouracil, 5-methoxy-ethoxy-methyl-uracil, 5-propynyl deoxyuridine, pseudoisocytidine, 5-azacytidine, 5-(1-propynyl)cytidine, 2′-deoxypseudouridine, 4-thio-deoxythymidine, 4-thio-deoxyuridine, and the like, and other substituted pyrimidines as disclosed in Freier et al, 1997 (Nucleic Acids Res. 25:4429-4443). Purine or pyrimidine nucleosides also include phosphoramidite derivatives used in oligonucleotide synthesis using standard methods.

“Nucleoside” also includes nucleosides having substituted ribose sugars (bicyclic or otherwise). Some representative patents and publications that teach the preparation of non-bicyclic modified sugars include, but are not limited to, U.S. Pat. Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; 5,700,920; and 6,600,032; and WO 2005/121371. Some representative patents and publications that teach the preparation of bicyclic modified sugars include, but are not limited to, ‘locked nucleic acids’, such as those described in WO 99/14226, WO 00/56746, WO 00/56748, WO 01/25248, WO 0148190, WO 02/28875, WO 03/006475, WO 03/09547, WO 2004/083430, U.S. Pat. No. 6,268,490, U.S. Pat. No. 6,794499, U.S. Pat. No. 7,034,133. Other examples of substituted ribose sugars are described in, for example, Freier, 1997 (Nucleic Acids Res. 25:4429-4443) and Herdewijn et al., 2000. (Antisense Nucleic Acid Drug Dev 10:297-310) both of which are incorporated by reference herein.

A ‘nucleotide’ refers to a nucleoside having an internucleoside linkage group bonded through the carbon-5 of the sugar ring, usually a mono-, di- or tri-phosphate, and may be suitable for enzymatic polymerization. In other examples, the nucleotides may be phosphoramidites, suitable for non-enzymatic polymerization or synthesis of nucleic acid polymers.

An internucleoside linkage group refers to a group capable of coupling two nucleosides, as part of an oligonucleotide backbone. Examples of internucleoside linkage groups are described by Praseuth et al (Biochimica et Biophysica Acta 1489:181-206) and Summerton et al 1997. (Antisense and Nucleic Acid Drug Dev 7:187-195), both of which are incorporated herein by reference. For example, phosphodiester (PO₄—), phosphorothioate (PO3_(s)-), phosphoramidate (N3′-P5′) (PO₃NH) and methylphosphonate (PO₃CH₃), peptidic linkages (“PNA”), and the like; see, for example, U.S. Pat, No. 5,969,118. Inclusion of such modified linkage groups, modified ribose sugars or nitrogenous bases in an oligonucleotide may reduce the rate of hydrolysis of the oligonucleotide in vitro or in vivo.

An “allele” is one of a pair, or one of a series of different forms of a given locus, marker or polymorphism. In a diploid organism or cell, the members of an allelic pair occupy corresponding positions (loci) on a pair of homologous chromosomes. If these alleles are identical, the organism is said to be ‘homozygous’ for that allele; if they differ, the organism or cell is said to be ‘heterozygous’ for that allele.

A “haplotype” is a set of alleles of closely linked loci on a chromosome that are generally inherited together. For example, a polymorphic allele at a first site in a nucleic acid sequence on the chromosome may be found to be associated with another polymorphic allele at a second site on the same chromosome, at a frequency other than would be expected for a random association (e.g. “linkage equilibrium”). These two polymorphic alleles may be described as being in linkage disequilibrium (LD). A haplotype may comprise two, three, four or more alleles. The set of alleles in a haplotype along a given segment of a chromosome are generally transmitted to progeny together unless there has been a recombination event.

A “haplogroup” is a group of similar haplotypes that share a common ancestor and that all share the same allele or set of alleles.

A human nucleic acid sequence for “normal” or “wild-type” HTT is exemplified by GenBank reference sequences NM_002111.7 (mRNA) and NC_000004.12 and NT_006051.19 (genomic). The human wild-type HTT protein is exemplified by GenPept reference sequence NP_002102.4. Other examples of such sequences will be available from these or similar databases, or as obtained by sequencing a sample comprising HTT nucleic acid or protein. Subjects with HD are usually heterozygous for the mutant HTT allele of the sequence.

A differentiating polymorphism is a variation in a nucleotide sequence that permits differentiation between a ‘wild-type’ and mutant allele of a nucleic acid sequence. Differentiating polymorphisms may include insertions or deletions of one or a few nucleotides in a sequence, or changes in one or a few nucleotides in a sequence.

A “single nucleotide polymorphism” or “SNP” is a single nucleotide variation between the genomes of individuals of the same species. In some cases, a SNP may be a single nucleotide deletion or insertion. In general, SNPs occur relatively frequently in genomes and thus contribute to genetic diversity. The density of SNPs in the human genome is estimated to be approximately 1 per 1,000 base pairs. In addition, SNPs are thought to be spaced relatively uniformly throughout the genome. Furthermore, SNPs are thought to be mutationally more stable than other polymorphisms, lending their use to association studies in which linkage disequilibrium between markers and an unknown variant is used to map disease-causing mutations. SNPs may have two, three or four alleles, or (although it may be possible to have three or four different forms of a SNP, corresponding to the different nucleotides), thus facilitating genotyping (by a simple plus/minus assay rather than a length measurement) and automation. The location of a SNP is generally flanked by highly conserved sequences. An individual may be homozygous or heterozygous for an allele at each SNP location. A heterozygous SNP allele is an example of a differentiating polymorphism.

Those of ordinary skill in the art will recognize that nucleic acid molecules are double-stranded and therefore reference to a particular SNP site on a strand also refers to the corresponding site on the complementary strand. Thus, reference may be made to either strand to refer to a particular SNP site or position, SNP allele, or nucleotide sequence, such as those set forth herein.

The sequences (SEQ ID NOs: 1-5) provided in TABLE 1 provide positive strand genomic DNA sequences comprising and flanking the selected polymorphisms illustrated in a 5′ to 3′ orientation that define the A1, A2 and A3a HD haplotypes of the HTT gene.

TABLE 1 The target DNA sequences for selected polymorphisms that define the A1, A2 and A3a HD haplotypes. The site of the polymorphism is defined in brackets (minor allele/major allele). SEQ ID NO: SNP Target DNA Sequence (5′ to 3′) 1 rs72239206 tgacagttgtatttttgtttgtgac(—/ and actt)acgtattatctgttaaaacattttc 527 2 rs363107 tcttaaacttttaaatgccatttgatcttt(g/a) aaaatatatgttttaatagtgtattttaag 3 rs362313 ccctcagcgagcaagtcaagctcttcacag(t/c) gatgtcttacaagcgcagagggctctgtga 4 rs2530595 gctttgtccctcccccgcttcctccctctg(t/c) ggggaggacccgggaccacagctgctggcc 5 rs113407847 ggagagactccactctgaatggggccggga(g/a) gtggggaggactccatttcagatggggtcg

The sequences provided in TABLE 2 may be useful to a person skilled in the art, to design one or more nucleic acid silencing agents that specifically hybridize to a differentiating polymorphism that defines the A1, A2 or A3 HD haplotypes.

TABLE 2 The reverse complement sequence for selected polymorphisms that define the A1, A2 and A3 HD haplotypes. The site of the polymorphism is defined in brackets. SEQ ID Reverse Complement of the target NO: SNP DNA Sequence (5′ to 3′) 6 rs72239206 gaaaatgttttaacagataatac[GT] gtcacaaacaaaaatacaactgtca 7 rs363107 cttaaaatacactattaaaacatatatttt[c] aaagatcaaatggcatttaaaagtttaaga 8 rs362313 tcacagagccctctgcgcttgtaagacatc[a] ctgtgaagagcttgacttgctcgctgaggg 9 rs2530595 ggccagcagctgtggtcccgggtcctcccc[a] cagagggaggaagcgggggagggacaaagc 10 rs113407847 cgaccccatctgaaatggagtcctccccac[c] tcccggccccattcagagtggagtctctcc

Examples of nucleic acid silencing agents are provided in TABLES 3-7. ASO are examples of nucleic acid silencing agents according to some embodiments of the present invention. Generally, ASOs may be about 20 nucleotides, but may range from about 12 to about 25 nucleotides, or any length in between. For example, an ASO may be 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length, with the proviso that the ASO selectively differentiate the nucleic acid molecules at the polymorphism.

TABLE 3 Exemplary ASO sequences that target the rs72239206 polymorphism, which defines the A1 HD haplotype. The location of the specific allele is indicated in upper case font. SEQ ID ASO (5′-3′) targeting NO: rs72239206 11 gttttaacagataatacGTg 12 ttttaacagataatacGTgt 13 tttaacagataatacGTgtc 14 ttaacagataatacGTgtca 15 taacagataatacGTgtcac 16 aacagataatacGTgtcaca 17 acagataatacGTgtcacaa 18 cagataatacGTgtcacaaa 19 agataatacGTgtcacaaac 20 gataatacGTgtcacaaaca 21 ataatacGTgtcacaaacaa 22 taatacGTgtcacaaacaaa 23 aatacGTgtcacaaacaaaa 24 atacGTgtcacaaacaaaaa 25 tacGTgtcacaaacaaaaat 26 acGTgtcacaaacaaaaata 27 cGTgtcacaaacaaaaatac 28 ttttaacagataatacGTg 29 tttaacagataatacGTgt 30 ttaacagataatacGTgtc 31 taacagataatacGTgtca 32 aacagataatacGTgtcac 33 acagataatacGTgtcaca 34 cagataatacGTgtcacaa 35 agataatacGTgtcacaaa 36 gataatacGTgtcacaaac 37 ataatacGTgtcacaaaca 38 taatacGTgtcacaaacaa 39 aatacGTgtcacaaacaaa 40 atacGTgtcacaaacaaaa 41 tacGTgtcacaaacaaaaa 42 acGTgtcacaaacaaaaat 43 cGTgtcacaaacaaaaata 44 tttaacagataatacGTg 45 ttaacagataatacGTgt 46 taacagataatacGTgtc 47 aacagataatacGTgtca 48 acagataatacGTgtcac 49 cagataatacGTgtcaca 50 agataatacGTgtcacaa 51 gataatacGTgtcacaaa 52 ataatacGTgtcacaaac 53 taatacGTgtcacaaaca 54 aatacGTgtcacaaacaa 55 atacGTgtcacaaacaaa 56 tacGTgtcacaaacaaaa 57 acGTgtcacaaacaaaaa 58 cGTgtcacaaacaaaaat 59 ttaacagataatacGTg 60 taacagataatacGTgt 61 aacagataatacGTgtc 62 acagataatacGTgtca 63 cagataatacGTgtcac 64 agataatacGTgtcaca 65 gataatacGTgtcacaa 66 ataatacGTgtcacaaa 67 taatacGTgtcacaaac 68 aatacGTgtcacaaaca 69 atacGTgtcacaaacaa 70 tacGTgtcacaaacaaa 71 acGTgtcacaaacaaaa 72 cGTgtcacaaacaaaaa 73 taacagataatacGTg 74 aacagataatacGTgt 75 acagataatacGTgtc 76 cagataatacGTgtca 77 agataatacGTgtcac 78 gataatacGTgtcaca 79 ataatacGTgtcacaa 80 taatacGTgtcacaaa 81 aatacGTgtcacaaac 82 atacGTgtcacaaaca 83 tacGTgtcacaaacaa 84 acGTgtcacaaacaaa 85 cGTgtcacaaacaaaa 86 aacagataatacGTg 87 acagataatacGTgt 88 cagataatacGTgtc 89 agataatacGTgtca 90 gataatacGTgtcac 91 ataatacGTgtcaca 92 taatacGTgtcacaa 93 aatacGTgtcacaaa 94 atacGTgtcacaaac 95 tacGTgtcacaaaca 96 acGTgtcacaaacaa 97 cGTgtcacaaacaaa

TABLE 4 Exemplary ASO sequences that target the rs363107 polymorphism which defines the A2 HD haplotype. The specific allele is indicated in upper case font. SEQ ID ASO (5′-3′) targeting NO rs363107 98 ctattaaaacatatattttC 99 tattaaaacatatattttCa 100 attaaaacatatattttCaa 101 ttaaaacatatattttCaaa 102 taaaacatatattttCaaag 103 aaaacatatattttCaaaga 104 aaacatatattttCaaagat 105 aacatatattttCaaagatc 106 acatatattttCaaagatca 107 catatattttCaaagatcaa 108 atatattttCaaagatcaaa 109 tatattttCaaagatcaaat 110 atattttCaaagatcaaatg 111 tattttCaaagatcaaatgg 112 attttCaaagatcaaatggc 113 ttttCaaagatcaaatggca 114 tttCaaagatcaaatggcat 115 ttCaaagatcaaatggcatt 116 tCaaagatcaaatggcattt 117 Caaagatcaaatggcattta 118 tattaaaacatatattttC 119 attaaaacatatattttCa 120 ttaaaacatatattttCaa 121 taaaacatatattttCaaa 122 aaaacatatattttCaaag 123 aaacatatattttCaaaga 124 aacatatattttCaaagat 125 acatatattttCaaagatc 126 catatattttCaaagatca 127 atatattttCaaagatcaa 128 tatattttCaaagatcaaa 129 atattttCaaagatcaaat 130 tattttCaaagatcaaatg 131 attttCaaagatcaaatgg 132 ttttCaaagatcaaatggc 133 tttCaaagatcaaatggca 134 ttCaaagatcaaatggcat 135 tCaaagatcaaatggcatt 136 Caaagatcaaatggcattt 137 attaaaacatatattttC 138 ttaaaacatatattttCa 139 taaaacatatattttCaa 140 aaaacatatattttCaaa 141 aaacatatattttCaaag 142 aacatatattttCaaaga 143 acatatattttCaaagat 144 catatattttCaaagatc 145 atatattttCaaagatca 146 tatattttCaaagatcaa 147 atattttCaaagatcaaa 148 tattttCaaagatcaaat 149 attttCaaagatcaaatg 150 ttttCaaagatcaaatgg 151 tttCaaagatcaaatggc 152 ttCaaagatcaaatggca 153 tCaaagatcaaatggcat 154 Caaagatcaaatggcatt 155 ttaaaacatatattttC 156 taaaacatatattttCa 157 aaaacatatattttCaa 158 aaacatatattttCaaa 159 aacatatattttCaaag 160 acatatattttCaaaga 161 catatattttCaaagat 162 atatattttCaaagatc 163 tatattttCaaagatca 164 atattttCaaagatcaa 165 tattttCaaagatcaaa 166 attttCaaagatcaaat 167 ttttCaaagatcaaatg 168 tttCaaagatcaaatgg 169 ttCaaagatcaaatggc 170 tCaaagatcaaatggca 171 Caaagatcaaatggcat 172 taaaacatatattttC 173 aaaacatatattttCa 174 aaacatatattttCaa 175 aacatatattttCaaa 176 acatatattttCaaag 177 catatattttCaaaga 178 atatattttCaaagat 179 tatattttCaaagatc 180 atattttCaaagatca 181 tattttCaaagatcaa 182 attttCaaagatcaaa 183 ttttCaaagatcaaat 184 tttCaaagatcaaatg 185 ttCaaagatcaaatgg 186 tCaaagatcaaatggc 187 Caaagatcaaatggca 188 aaaacatatattttC 189 aaacatatattttCa 190 aacatatattttCaa 191 acatatattttCaaa 192 catatattttCaaag 193 atatattttCaaaga 194 tatattttCaaagat 195 atattttCaaagatc 196 tattttCaaagatca 197 attttCaaagatcaa 198 ttttCaaagatcaaa 199 tttCaaagatcaaat 200 ttCaaagatcaaatg 201 tCaaagatcaaatgg 202 Caaagatcaaatggc

TABLE 5 Exemplary ASO sequences that target the rs362313 polymorphism which defines the A2 HD haplotype. The specific allele is indicated in upper case font. ASO (5′-3′) targeting SEQ ID NO rs362313 203 tctgcgcttgtaagacatcA 204 ctgcgcttgtaagacatcAc 205 tgcgcttgtaagacatcAct 206 gcgcttgtaagacatcActg 207 cgcttgtaagacatcActgt 208 gcttgtaagacatcActgtg 209 cttgtaagacatcActgtga 210 ttgtaagacatcActgtgaa 211 tgtaagacatcActgtgaag 212 gtaagacatcActgtgaaga 213 taagacatcActgtgaagag 214 aagacatcActgtgaagagc 215 agacatcActgtgaagagct 216 gacatcActgtgaagagctt 217 acatcActgtgaagagcttg 218 catcActgtgaagagcttga 219 atcActgtgaagagcttgac 220 tcActgtgaagagcttgact 221 cActgtgaagagcttgactt 222 Actgtgaagagcttgacttg 223 ctgcgcttgtaagacatcA 224 tgcgcttgtaagacatcAc 225 gcgcttgtaagacatcAct 226 cgcttgtaagacatcActg 227 gcttgtaagacatcActgt 228 cttgtaagacatcActgtg 229 ttgtaagacatcActgtga 230 tgtaagacatcActgtgaa 231 gtaagacatcActgtgaag 232 taagacatcActgtgaaga 233 aagacatcActgtgaagag 234 agacatcActgtgaagagc 235 gacatcActgtgaagagct 236 acatcActgtgaagagctt 237 catcActgtgaagagcttg 238 atcActgtgaagagcttga 239 tcActgtgaagagcttgac 240 cActgtgaagagcttgact 241 Actgtgaagagcttgactt 242 tgcgcttgtaagacatcA 243 gcgcttgtaagacatcAc 244 cgcttgtaagacatcAct 245 gcttgtaagacatcActg 246 cttgtaagacatcActgt 247 ttgtaagacatcActgtg 248 tgtaagacatcActgtga 249 gtaagacatcActgtgaa 250 taagacatcActgtgaag 251 aagacatcActgtgaaga 252 agacatcActgtgaagag 253 gacatcActgtgaagagc 254 acatcActgtgaagagct 255 catcActgtgaagagctt 256 atcActgtgaagagcttg 257 tcActgtgaagagcttga 258 cActgtgaagagcttgac 259 Actgtgaagagcttgact 260 gcgcttgtaagacatcA 261 cgcttgtaagacatcAc 262 gcttgtaagacatcAct 263 cttgtaagacatcActg 264 ttgtaagacatcActgt 265 tgtaagacatcActgtg 266 gtaagacatcActgtga 267 taagacatcActgtgaa 268 aagacatcActgtgaag 269 agacatcActgtgaaga 270 gacatcActgtgaagag 271 acatcActgtgaagagc 272 catcActgtgaagagct 273 atcActgtgaagagctt 274 tcActgtgaagagcttg 275 cActgtgaagagcttga 276 Actgtgaagagcttgac 277 cgcttgtaagacatcA 278 gcttgtaagacatcAc 279 cttgtaagacatcAct 280 ttgtaagacatcActg 281 tgtaagacatcActgt 282 gtaagacatcActgtg 283 taagacatcActgtga 284 aagacatcActgtgaa 285 agacatcActgtgaag 286 gacatcActgtgaaga 287 acatcActgtgaagag 288 catcActgtgaagagc 289 atcActgtgaagagct 290 tcActgtgaagagctt 291 cActgtgaagagcttg 292 Actgtgaagagcttga 293 gcttgtaagacatcA 294 cttgtaagacatcAc 295 ttgtaagacatcAct 296 tgtaagacatcActg 297 gtaagacatcActgt 298 taagacatcActgtg 299 aagacatcActgtga 300 agacatcActgtgaa 301 gacatcActgtgaag 302 acatcActgtgaaga 303 catcActgtgaagag 304 atcActgtgaagagc 305 tcActgtgaagagct 306 cActgtgaagagctt 307 Actgtgaagagcttg

TABLE 6 Exemplary ASO sequences that target the rs2530595 polymorphism which defines the A2 HD haplotype. The specific allele is indicated in upper case font. ASO (5′-3′) targeting SEQ ID NO: rs2530595 308 gtggtcccgggtcctccccA 309 tggtcccgggtcctccccAc 310 ggtcccgggtcctccccAca 311 gtcccgggtcctccccAcag 312 tcccgggtcctccccAcaga 313 cccgggtcctccccAcagag 314 ccgggtcctccccAcagagg 315 cgggtcctccccAcagaggg 316 gggtcctccccAcagaggga 317 ggtcctccccAcagagggag 318 gtcctccccAcagagggagg 319 tcctccccAcagagggagga 320 cctccccAcagagggaggaa 321 ctccccAcagagggaggaag 322 tccccAcagagggaggaagc 323 ccccAcagagggaggaagcg 324 cccAcagagggaggaagcgg 325 ccAcagagggaggaagcggg 326 cAcagagggaggaagcgggg 327 Acagagggaggaagcggggg 328 tggtcccgggtcctccccA 329 ggtcccgggtcctccccAc 330 gtcccgggtcctccccAca 331 tcccgggtcctccccAcag 332 cccgggtcctccccAcaga 333 ccgggtcctccccAcagag 334 cgggtcctccccAcagagg 335 gggtcctccccAcagaggg 336 ggtcctccccAcagaggga 337 gtcctccccAcagagggag 338 tcctccccAcagagggagg 339 cctccccAcagagggagga 340 ctccccAcagagggaggaa 341 tccccAcagagggaggaag 342 ccccAcagagggaggaagc 343 cccAcagagggaggaagcg 344 ccAcagagggaggaagcgg 345 cAcagagggaggaagcggg 346 Acagagggaggaagcgggg 347 ggtcccgggtcctccccA 348 gtcccgggtcctccccAc 349 tcccgggtcctccccAca 350 cccgggtcctccccAcag 351 ccgggtcctccccAcaga 352 cgggtcctccccAcagag 353 gggtcctccccAcagagg 354 ggtcctccccAcagaggg 355 gtcctccccAcagaggga 356 tcctccccAcagagggag 357 cctccccAcagagggagg 358 ctccccAcagagggagga 359 tccccAcagagggaggaa 360 ccccAcagagggaggaag 361 cccAcagagggaggaagc 362 ccAcagagggaggaagcg 363 cAcagagggaggaagcgg 364 Acagagggaggaagcggg 365 gtcccgggtcctccccA 366 tcccgggtcctccccAc 367 cccgggtcctccccAca 368 ccgggtcctccccAcag 369 cgggtcctccccAcaga 370 gggtcctccccAcagag 371 ggtcctccccAcagagg 372 gtcctccccAcagaggg 373 tcctccccAcagaggga 374 cctccccAcagagggag 375 ctccccAcagagggagg 376 tccccAcagagggagga 377 ccccAcagagggaggaa 378 cccAcagagggaggaag 379 ccAcagagggaggaagc 380 cAcagagggaggaagcg 381 Acagagggaggaagcgg 382 tcccgggtcctccccA 383 cccgggtcctccccAc 384 ccgggtcctccccAca 385 cgggtcctccccAcag 386 gggtcctccccAcaga 387 ggtcctccccAcagag 388 gtcctccccAcagagg 389 tcctccccAcagaggg 390 cctccccAcagaggga 391 ctccccAcagagggag 392 tccccAcagagggagg 393 ccccAcagagggagga 394 cccAcagagggaggaa 395 ccAcagagggaggaag 396 cAcagagggaggaagc 397 Acagagggaggaagcg 398 cccgggtcctccccA 399 ccgggtcctccccAc 400 cgggtcctccccAca 401 gggtcctccccAcag 402 ggtcctccccAcaga 403 gtcctccccAcagag 404 tcctccccAcagagg 405 cctccccAcagaggg 406 ctccccAcagaggga 407 tccccAcagagggag 408 ccccAcagagggagg 409 cccAcagagggagga 410 ccAcagagggaggaa 411 cAcagagggaggaag 412 Acagagggaggaagc

TABLE 7 Exemplary ASO sequences that target the rs113407847 polymorphism, which defines the A3a HD haplotype. The specific allele is indicated in upper case font. ASO (5′-3′) targeting SEQ ID NO rs113407847 413 gaaatggagtcctccccacC 414 aaatggagtcctccccacCt 415 aatggagtcctccccacCtc 416 atggagtcctccccacCtcc 417 tggagtcctccccacCtccc 418 ggagtcctccccacCtcccg 419 gagtcctccccacCtcccgg 420 agtcctccccacCtcccggc 421 gtcctccccacCtcccggcc 422 tcctccccacCtcccggccc 423 cctccccacCtcccggcccc 424 ctccccacCtcccggcccca 425 tccccacCtcccggccccat 426 ccccacCtcccggccccatt 427 cccacCtcccggccccattc 428 ccacCtcccggccccattca 429 cacCtcccggccccattcag 430 acCtcccggccccattcaga 431 cCtcccggccccattcagag 432 Ctcccggccccattcagagt 433 aaatggagtcctccccacC 434 aatggagtcctccccacCt 435 atggagtcctccccacCtc 436 tggagtcctccccacCtcc 437 ggagtcctccccacCtccc 438 gagtcctccccacCtcccg 439 agtcctccccacCtcccgg 440 gtcctccccacCtcccggc 441 tcctccccacCtcccggcc 442 cctccccacCtcccggccc 443 ctccccacCtcccggcccc 444 tccccacCtcccggcccca 445 ccccacCtcccggccccat 446 cccacCtcccggccccatt 447 ccacCtcccggccccattc 448 cacCtcccggccccattca 449 acCtcccggccccattcag 450 cCtcccggccccattcaga 451 Ctcccggccccattcagag 452 aatggagtcctccccacC 453 atggagtcctccccacCt 454 tggagtcctccccacCtc 455 ggagtcctccccacCtcc 456 gagtcctccccacCtccc 457 agtcctccccacCtcccg 458 gtcctccccacCtcccgg 459 tcctccccacCtcccggc 460 cctccccacCtcccggcc 461 ctccccacCtcccggccc 462 tccccacCtcccggcccc 463 ccccacCtcccggcccca 464 cccacCtcccggccccat 465 ccacCtcccggccccatt 466 cacCtcccggccccattc 467 acCtcccggccccattca 468 cCtcccggccccattcag 469 Ctcccggccccattcaga 470 atggagtcctccccacC 471 tggagtcctccccacCt 472 ggagtcctccccacCtc 473 gagtcctccccacCtcc 474 agtcctccccacCtccc 475 gtcctccccacCtcccg 476 tcctccccacCtcccgg 477 cctccccacCtcccggc 478 ctccccacCtcccggcc 479 tccccacCtcccggccc 480 ccccacCtcccggcccc 481 cccacCtcccggcccca 482 ccacCtcccggccccat 483 cacCtcccggccccatt 484 acCtcccggccccattc 485 cCtcccggccccattca 486 Ctcccggccccattcag 487 tggagtcctccccacC 488 ggagtcctccccacCt 489 gagtcctccccacCtc 490 agtcctccccacCtcc 491 gtcctccccacCtccc 492 tcctccccacCtcccg 493 cctccccacCtcccgg 494 ctccccacCtcccggc 495 tccccacCtcccggcc 496 ccccacCtcccggccc 497 cccacCtcccggcccc 498 ccacCtcccggcccca 499 cacCtcccggccccat 500 acCtcccggccccatt 501 cCtcccggccccattc 502 Ctcccggccccattca 503 ggagtcctccccacC 504 gagtcctccccacCt 505 agtcctccccacCtc 506 gtcctccccacCtcc 507 tcctccccacCtccc 508 cctccccacCtcccg 509 ctccccacCtcccgg 510 tccccacCtcccggc 511 ccccacCtcccggcc 512 cccacCtcccggccc 513 ccacCtcccggcccc 514 cacCtcccggcccca 515 acCtcccggccccat 516 cCtcccggccccatt 517 Ctcccggccccattc

The invention provides one or more nucleic acid silencing agents having a sequence of one or more than one of SEQ ID NO: 6-517 or portions or fragments thereof.

In a further aspect, the invention provides the use of one or more ASOs having a sequence of one or more than one of SEQ ID NO: 6-517 to treat, prevent or ameliorate HD.

TABLE 8 The target DNA sequences for selected polymorphisms that define the A1, A2 and A3 HD haplotypes. Target polymorphic variant shown. SEQ ID NO: SNP Target DNA Sequence (5′ to 3′) 522 rs72239206 tgacagttgtatttttgtttgtgacacgtatt atctgttaaaacattttc 523 rs363107 tcttaaacttttaaatgccatttgatctttga aaatatatgttttaatagtgtattttaag 524 rs362313 ccctcagcgagcaagtcaagctcttcacagtg atgtcttacaagcgcagagggctctgtga 525 rs2530595 gctttgtccctcccccgcttcctccctctgtg gggaggacccgggaccacagctgctggcc 526 rs113407847 ggagagactccactctgaatggggccgggagg tggggaggactccatttcagatggggtcg

Materials and Methods

The following methods were employed respect to the Examples described herein.

Genotyping and Haplotype Assignment in Canadian Subjects

91 SNPs were genotyped in >1000 Canadian Caucasian HD patients and relatives using the Illumina GoldenGate genotyping array and BeadXpress platform. Genotypes were called using Illumina GenomeStudio software, and 91-SNP haplotypes were reconstructed using PHASE V2.1. Haplotypes were manually annotated, then phased to CAG repeat length and confirmed for sequence identity by familial relationship. 28/91 SNPs in our original panel are rare or occur predominantly in non-Caucasian ethnic groups, leaving 63 SNPs of >1% frequency in European populations (1000 Genomes). 51 of these 63 common SNPs occur within the HTT gene sequence, and were used for annotation of intragenic haplotypes within the extended 63 SNP haplotype.

Analysis of HTT Haplotypes in 1000 Genomes

Variant call files (VCFs) encompassing the HTT gene region (GRCh37 3034088-3288007, +/− 50 kb of HTT gene, SHAPEIT haplotypes) were downloaded from the 1000 Genomes Project Consortium (Phase I) using the Data Slicer tool and analyzed in the R statistical computing environment. 2166 phased haplotypes of chromosome 4 were available from 1083 individuals. Chromosomes bearing the intragenic A1 haplotype were identified using rs362307, a previously defined tagging SNP [24]. SNPs present on at least 90% of the 76 chromosomes containing rs362307[T] (i.e. SNPs present on at least 70 of 76 chromosomes) but also present on less than 100 of all 2166 chromosomes were identified as candidate A1 markers for further analysis. A2 chromosomes were similarly identified using rs2798235 and rs363080, the defining A2 markers from manual 63-SNP haplotype annotation of the Canadian Caucasian cohort. Discovery of linked A2 variants followed a similar strategy as for linked A1 variants. A3 chromosomes were identified among A haplogroup chromosomes by exclusion of all chromosomes bearing any specific A haplotype-defining SNPs in our 63-SNP panel. A1, A2, and A3 subtype markers were defined as any SNP present on a subset of each haplotype, but on no other chromosomes in the complete 1000 Genomes data set. Following identification of all A1, A2, and A3 variants, phased genotypes of intragenic HTT SNPs present at ≧5% EUR frequency in the 1000 Genomes Phase I data set were extracted from all 738 European chromosomes and manually annotated in comparison to our directly genotyped 63-SNP haplotype data.

Genotyping and Haplotype Assignment in European Subjects

200 Swedish, 100 French, and 291 Italian HD family members were identified from the UBC HD BioBank and in cooperation with IRCCS Neuromed in Pozzilli, Italy. All French and Swedish samples were collected in their respective countries of origin for HD gene mapping studies in the 1990s. Of these samples, 120 Swedish, 76 French, 22 Finnish, and 209 Italian family members were identified as phaseable for haplotype and CAG repeat length. All haplotype-defining 63 SNPs genotyped in the Canadian Caucasian cohort were genotyped in the selected European samples, with addition of 6 novel A1 and A1 subtype SNPs, 5 novel A2 and A2 subtype SNPs, and a novel A3 subtype SNP. European samples were additionally genotyped at 15 SNPs not present in the 63 SNP panel but necessary for reconstruction of haplotypes inferred in prior 4p16.3 locus genotyping [22]. Haplotypes in European samples were reconstructed with PHASE v2.1 and manually annotated as for the Canadian Caucasian cohort.

Direct Genotyping of HTT A1 Variants

A1 markers rs149109767 and rs72239206 are biallelic indels, and were genotyped by fragment analysis in phaseable samples from the UBC HD BioBank with 63-SNP haplotype data. Genotypes of rs149109767 and rs72239206 were phased to SNP haplotype and CAG repeat length by familial relationship. In total, 454 phased, nonredundant HD chromosomes and 652 nonredundant control chromosomes were directly genotyped and phased to CAG repeat length. PCR products containing rs149109767 were amplified using dye-labeled del2642F (6FAM-GCTGGGGAACAGCATCACACCC identified as SEQ ID NO: 518) and del2642 R (CCTGGAGTTGACTGGAGACTTG identified as SEQ ID NO: 519). Products containing rs72239206 were amplified with delACTT 3F (GAGGATTGACCACACCACCT identified as SEQ ID NO: 520) and dye-labeled delACTT 3R (HEX-ATGTGGCCATTTGACACGATA identified as SEQ ID NO: 521). Primers were multiplexed for ease of genotyping, and PCR products analyzed by ABI 3730xl BioAnalyzer with GeneMapper software.

Design of A1-Targeted Antisense Oligonucleotides

Locked nucleic acid (LNA) gapmer ASOs targeting the mutant ΔACTT (rs72239206), rs363107, rs362313, rs2530595, rs113407847 minor alleles and corresponding major allele reference sequence were designed in-house and synthesized by Exiqon on a fee-for-service basis. Oligos were resuspended in 1X TE and stored at −20 C between transfection experiments.

Passive Transfection of HD Patient Cells with A1-Targeted ASOs

Human HD lymphoblasts previously haplotyped as A1/C1 haplotypes (Coriell NIGMS Human Genetic Cell Repository ID #GM03620, CAG lengths 59/18), were cultured in 2 mL complete RPMI media (500,000 cells in 15% FBS+1% pen-strep) with 78 nM, 312 nM, or 1250 nM varying doses of ASO sequences were cultured in 2 mL complete RPMI media (500,000 cells in 15% FBS+1% pen-strep) with 78 nM, 312 nM, or 1250nM varying doses of ASO sequences. Cells were incubated 120 h, and harvested for Western blot analysis as described previously [25]. Anti-non-muscle myosin IIA (Abeam ab24762) immunoblotting was used as a loading control.

Active Transfection of HD Patient Cells with A1, A2, or A3a-Targeted ASOs

Human HD lymphoblasts previously haplotyped as either A1/C1 haplotypes (Coriell NIGMS Human Genetic Cell Repository ID #GM03620, CAG lengths 59/18), A2/C haplotypes (Coriell NIGMS Human Genetic Cell Repository ID #GM02150, CAG lengths 44/18) or A3a/C haplotypes (Coriell NIGMS Human Genetic Cell Repository ID #GM04724, CAG lengths 67/15) were cultured in 2 mL complete RPMI media (15% FBS+1% pen-strep). 1-5×106 cells were transfected by electroporation using the Amaxa Nucleofector Kit C (VCA-1004) for each ASO dose in 100 μL nucleofector solution. Cells were incubated 72 or 120 h, and harvested for Western blot analysis as described previously [25]. Anti-non-muscle myosin IIA (Abeam ab24762) immunoblotting was used as a loading control.

Allele-Specific HTT mRNA Quantification

For FIG. 3, transfected cells were re-cultured for 24 h, and half of each culture pelleted for RNA extraction, cDNA synthesis, and allele-specific qPCR. Remaining cell culture was propagated for protein analysis at 72 h. For all other figures, transfected cells were harvested at 120 h for RNA extraction, cDNA synthesis, and allele-specific qPCR. A1 and C1 HTT mRNA transcript was quantified in quadruplicate for each dose of each experiment using TaqMan probe designed to rs362331 (ABI, C_(——)2231945_10) and normalized to GAPDH (ABI, 4333764F). All experiments were performed three time, with two transfection replicates for each data point in each experiment (n=4-6 for each data point).

Allele-Specific HTT Protein Quantification

Human HD lymphoblasts previously haplotyped as either A1/C haplotypes (Coriell NIGMS Human Genetic Cell Repository ID #GM03620, CAG lengths 59/18), A2/C haplotypes (Coriell NIGMS Human Genetic Cell Repository ID #GM02150, CAG lengths 44/18), A3a/C haplotypes (Coriell NIGMS Human Genetic Cell Repository ID #GM04724, CAG lengths 67/15) were cultured in 2 mL complete RPMI media (15% FBS+1% pen-strep). 1×106 cells were transfected by electroporation using the Amaxa Nucleofector Kit C (VCA-1004) for each ASO dose in 100 μL nucleofector solution. Transfected lymphoblast cultures were harvested at 72 h (FIG. 3) or 120 h (FIGS. 5-9) and pelleted for quantitative Western blot analysis. Cells were pelleted by centrifugation at 250 g for 5 min at 4 C and stored at−80° C. Proteins were extracted by lysis with SDP+buffer and 30-60 μg of total protein was resolved on 10% low-BIS acrylamide gels and transferred to 0.45 μm nitrocellulose membrane as previously described (Carroll et al., 2011). Membranes were blocked with 5% milk in PBS, and then blotted with anti-HTT antibody 2166 (Millipore) for detection of HTT. Anti-non-muscle myosin IIA (Abcam ab24762) immunoblotting was used as a loading control. Secondary antibodies, IR dye 800CW goat anti-mouse (Rockland 610-131-007) and AlexaFluor 680 goat anti-rabbit (Molecular Probes A21076), were used for detection and membranes were scanned using the LiCor Odyssey Infrared Imaging system. Licor Image Studio Lite was used to quantify the intensity of the individual bands (n=3-6 for each data point). Figure data are presented as mean+/−SEM. Two way ANOVA with Bonferroni post hoc test was performed for each dose series and p-values illustrated with **and*** for p=0.01 and p=0.001, respectively. Representative images for HTT were chosen.

In Vivo ASO Treatment with ASOs

YAC128 HD model mice [26] were maintained under a 12 h light: 12 h dark cycle in a clean facility and given free access to food and water. Experiments were performed with the approval of the animal care committee of the University of British Columbia. ASOs were delivered by intracerebroventricular injection as in [19] at the indicated doses diluted to a final volume of 10 μl in sterile PBS. Four weeks later, brains were collected and sectioned in a 1 mm coronal rodent brain matrix (ASI Instruments). The most anterior 2 mm section, containing mostly olfactory bulb, was discarded. The next most anterior 2 mm section, containing mostly cortex and striatum, was divided into hemispheres and lysed as previously described [19]. 40 μg total protein was used for allele-specific HTT protein quantification as above.

The following examples are provided for illustrative purposes and are not intended to be limiting as such:

EXAMPLES Example 1 SNPs Across HTT Represent Gene-Spanning Haplotypes and the A1, A2, and A3a Haplotypes Represent the Most Common Gene-Spanning HD Haplotypes

In order to determine the frequency and heterozygosity of different allele-specific HTT targets relative to one another, we sought to establish the haplotypes for a large number of common polymorphisms across the HTT gene region. Various partial haplotypes have been constructed across HTT, but sequence identity and recombination between these haplotypes has remained ambiguous due to low marker density across the ˜170 kb gene sequence. We previously genotyped 91 SNPs across the HTT gene region [18], of which 63 are present at greater than 1% frequency in European populations [27]. Of these 63 common SNPs, 51 are located between the start of the HTT 5′ UTR and the end of the 3UTR (chr4:3076408-3245687, GRCh37) (not shown). In total, 527 Canadian HD patients and 305 control relatives from the UBC HD Biobank were genotyped and phased at all 63 SNPs for this study. Using patterns of familial segregation, we reconstructed gene-spanning haplotypes at all 63 SNPs for 293 unrelated CAG-expanded chromosomes (CAG>35) and 829 control chromosomes (CAG≦35) from Canadian individuals of European ancestry. The annotation of dense 63-SNP haplotypes replicated the major haplogroup assignments previously obtained using 22 tSNPs across the HTT gene region [24, 28], and confirmed that recombination between common haplotypes principally occurs extragenic to the HTT gene. For example, the A3 haplotype is frequently associated with a historical extragenic 5′ crossover with the C1 haplotype, whereas no common haplotype is observed with C1 recombined within the HTT gene sequence. Only 9/283 (3.2%) HD chromosomes and 25/829 (3.0%) control chromosomes in our Canadian cohort represent intragenic recombinants of gene-spanning HTT haplotypes, confirming that recombination within HTT is rare. Analysis of pairwise linkage disequilibrium (LD) between genotypes of all 63 SNPs in 1664 phased haplotypes from Canadian HD patients and controls reveals a ˜170 kb region of high LD (D′>0.9) from rs762855 to rs362303 (chr4: 3074795-3242307), indicating a haplotype block of exceedingly low recombination across the entire transcribed HTT sequence (not shown).

In contrast, stringent pairwise LD by correlation coefficient (r²) reveals a punctuated pattern of SNP disequilibrium within the HTT haplotype block, reflecting a diversity of haplotypes spanning the gene locus. Strikingly, SNPs in high pairwise correlation within HTT tag specific intragenic haplotypes. For example, rs2798235 and rs363080 represent unique markers of the A2 haplotype and are found in near-perfect pairwise correlation (r²=0.98), whereas both SNPs show low pairwise correlation with all other variants in the 63-SNP panel. Both SNPs are highly specific, linked markers of the A2 haplotype spanning the entire HTT gene. The observed pattern of high LD across HTT, and the presence of identical haplotypes tagged by unique sets of SNPs, shows that SNPs within HTT represent specific haplotypes or groups of haplotypes encompassing the entire HTT sequence, uninterrupted by historical recombination. Among Canadian subjects, 95.8% (271/283) of HD chromosomes and 95.9% (795/829) of control chromosomes conform to 20 specific non-recombinant haplotypes at 51 common intragenic SNPs and at exon 1 CCG repeat length (TABLE 9).

TABLE 9 shows 20 common intragenic haplotypes from the Canadian Caucasian cohort (51 SNPs). rs3856973 rs2285086 rs7659144 rs16843804 rs2024115 rs3733217 rs10015979 rs7691627 rs2798235 rs1936032 rs4690072 rs6446723 rs363070 rs363081 rs363080 rs363075 rs363064 3080173 3089259 3098321 3104390 3104568 3107334 3109442 3111410 3114832 3117168 3122507 3126813 3131573 3133627 3133911 3137674 3141410 A1 G A C C A C G G G C T T A G C G C A2a G A C C A C G G A C T T A G T A C A2b G A C C A C G G A C T T A G T G C A3 G A C C A C G G G C T T A G C G C A4a G A C C A C G G G C T T A G C G C A4b G A C C A C G G G C T T A A C G C A5a G A C C A C G G G C T T A G C G C A5b G A C C A C G G G C T T A G C G C A5c G A C C A C G G G C T T A G C G C B1 G A C C A T A G G C T T A G C G C B2 G A C C A C A G G C T T A G C G C C1 A G G T G C A A G C G C A G C G T C2a A G G C G C A A G C G C A G C G C C2b A G C C G C A A G G G C A G C G C C3a A G C C A C A A G C G C G G C G C C3b A G C C A C A A G C G C G G C G C C4 A G C C G C A A G C G C A G C G C C5 A G C C G C A A G C G C A G C G C C6 A G C C G C A A G G G C A G C G C C8 A G C T G C A A G C G C G G C G C rs363072 rs3025849 rs12502045 rs35892913 rs1143646 rs363102 rs11731237 rs4690073 rs363144 rs363099 rs3025837 rs363096 3142528 3143767 3147268 3148570 3148653 3149016 3151813 3160150 3161295 3162056 3174845 3180021 A1 A A C G T A T G T C A T A2a A A C A T G C G T C A C A2b A A C G T G C G T C A C A3 A A C G T A T G T C A T A4a A A C G G A T G T C A T A4b A A C G T A T G G C A T A5a A A C G T A T G T C A T A5b A A C G T A C G T C A T A5c A A C G T A C G T C A C B1 T A T G T A C G T C A T B2 T A T G T A C G T C A T C1 A A C G T A C A T T A C C2a T A C G T A C A T C A C C2b T A C G T A C A T C A C C3a A G C G T G C A T C A C C3b A G C G T G C A T C A C C4 T A C G T A C A T C A C C5 A A C G T G C A T C A C C6 T A C G T A C A T C A C C8 A A C G T A C A T T A C rs2298967 rs2298969 rs10488840 rs363125 rs6844859 rs363092 rs7685686 rs363088 rs362331 rs916171 rs362325 3185747 3186244 3186993 3189547 3190486 3196029 3207142 3210330 3215835 3216815 3219326 A1 T T G C T C A A T C G A2a T T G C T C A A T C G A2b T T G C T C A A T C G A3 T T G C T C A A T C G A4a T T G C T C A A T C G A4b T T G C T C A A T C G A5a T T G C T C A A T C G A5b T T G C T C A A T C G A5c T T G C T C G A T C G B1 T T G C T C A A T C G B2 T T G C T C A A T C G C1 C C G C T A G T C G G C2a T T A A C A G A C G G C2b T T A A C A G A C G C C3a T T A A C A G A C G C C3b T T A A C A G A C G C C4 T T A A C A G A C G G C5 T T G A C A G A C G G C6 T T A A C A G A C G G C8 C T G C C A G T C G G rs362275 rs362273 rs2276881 rs3121419 rs362272 rs362271 rs3775061 rs362310 rs362307 rs362306 rs362303 3224602 3227419 3231661 3232257 3234980 3235518 3238754 3239776 3241845 3242100 3242307 A1 C A G C G G G A T G C A2a C A G C G G G A C G C A2b C A G C G G G A C G C A3 C A G C G G G A C G C A4a C A G C G G G A C G C A4b C A G C G G G A C G C A5a C A A C G G G A C G C A5b C A A C G G G A C G C A5c C A G C G G G A C G C B1 C A G C G G G A C G C B2 C A G C G G G A C G C C1 T G G T A A A G C A C C2a C A G C G G G A C G T C2b C A G C G G G A C G T C3a C A G C G G G A C G T C3b C A G C G G G A C G T C4 C A G C G G G A C G T C5 C A G C G G G A C G C C6 C A G C G G G A C G T C8 T G G T A A A G C A C

We next determined the most frequent gene-spanning haplotypes occurring on HD chromosomes. Among 283 unrelated Canadian HD chromosomes, 48.1% (136/283) are found on the A1 haplotype marked by rs362307, 32.2% (91/283) are found on closely related A2a or A2b, and 12.0% (34/283) are found on A3. In total, 92.2% (261/283) of Canadian HD chromosomes are found on A1, A2, or A3 haplotypes spanning HTT. Among control chromosomes, only 8.0% are A1, 16.4% are A2a or A2b, and 13.1% are A3. Haplotypes A4 and A5, each present on 6.3% of control chromosomes, are never observed on Canadian HD chromosomes. Notably, A1 and A2a represent the most genetically distant haplotypes within the A haplogroup, despite representing the most frequent HD haplotypes. Haplogroup B is a distinct genetic lineage in 5.3% of HTT controls, present on only 3/283 HD chromosomes in the Canadian cohort (1.1%). Haplogroup C is a complex collection of haplotypes constituting nearly half of unrelated control chromosomes (42.6%), but is found on only 3.2% of HD chromosomes. The most common intragenic haplotype among all annotations is C1, present on 29.8% of unrelated control chromosomes in the Canadian cohort.

Example 2 Identification of All Defining Intragenic Alleles on HD-Associated Haplotypes

Mutant HTT is enriched for gene-spanning A1 and A2 haplotypes relative to controls. This suggests that alleles found exclusively on these haplotypes may represent attractive targets for allele-specific silencing of mutant HTT. To determine all polymorphisms uniquely found on the most frequent HD-associated haplotypes (A1 and A2), we identified all chromosomes in the 1000 Genomes Project whole genome sequencing data bearing these haplotype-specific SNPs. In total, 2297 intragenic polymorphisms are annotated across HTT (chr4:3076408-3245687, GRCh37) in the 1000 Genomes Phase I data set.

In our 51-SNP panel, the A1 haplotype is uniquely defined by rs362307, a [T/C] SNP present in exon 67 and the 3′ UTR of HTT. Among all 1000 Genomes chromosomes, 3.5% (76/2166) carry this SNP. Among the 76 chromosomes bearing rs362307[T], 75 carry the glutamic acid deletion known as Δ2642 (rs149109767) and 74 carry a novel 4 bp intron deletion (rs72239206). Among all 2166 chromosomes, including those 76 bearing rs362307[T], Δ2642 is present on 77 and rs72239206 is present on 83. Therefore 97.4% (75/77) of chromosomes with Δ2642 and 89.2% (74/83) of those with rs72239206 also carry rs362307[T]. Both polymorphisms thus represent highly sensitive proxy markers of rs362307 (FIG. 1a ). No other SNPs were as strongly associated with rs362307. For example, the next most common SNP also present on at least 90% of the A1 chromosomes was found nonspecifically on 633/2166 chromosomes. Among SNPs less frequent than rs362307, one intragenic SNP (rs187059132) occurs specifically on a subset of 32/76 A1 chromosomes. Variants rs362307, rs149109767 (Δ2642), and rs72239206 (ΔACTT) are therefore highly specific for the A1 haplotype, having high pairwise correlation (r²>0.9) with each other but with no other SNPs in the 1000 Genomes data set. All three A1-defining polymorphisms are found almost exclusively on individuals of European or Admixed European ethnicity (TABLE 10), in agreement with the reported absence of rs149109767 (Δ2642) alleles in individuals of East Asian and black South African ancestry [28, 29].

TABLE 10 shows A1 allele counts (n) and relative frequencies (%) among the HD and control chromosomes from the UBC HD Biobank (labelled as CMMT HD chromosomes and CMMT normal chromosomes) and from normal chromosomes obtained from the 1000 Genomes Phase I sequence data. chromosomes rs362307 Δ2642 ΔACTT n n % n % n % CMMT HD chromosomes Caucasian 454 214 47.1% 217 47.8% 216 47.6% East Asian 53 0  0.0% 0  0.0% 0  0.0% Black African 19 0  0.0% 0  0.0% 0  0.0% CMMT normal chromosomes Caucasian 652 42  6.4% 43  6.6% 40  6.1% East Asian 94 0  0.0% 0  0.0% 0  0.0% Black African 211 0  0.0% 0  0.0% 0  0.0% 1000 Genomes normal chromsomes MXL Mexican 132 11 8.33% 11 8.33% 12 9.09% CEU CEPH (Caucasian, Utah) 170 14 8.24% 13 7.65% 13 7.65% GBR British 178 13 7.30% 13 7.30% 14 7.87% FIN Finnish 186 13 6.99% 13 6.99% 13 6.99% CLM Colombian 120 7 5.83% 7 5.83% 12 10.00%  TSI Toscan 178 10 5.62% 11 6.18% 11 6.18% PUR Puerto Rican 110 4 3.64% 4 3.64% 5 4.55% ASW African American 122 3 2.46% 3 2.46% 3 2.46% CHB Han Chinese in Beijing 194 1 0.52% 0 0.00% 0 0.00% CHS Han Chinese South 200 0 0.00% 0 0.00% 0 0.00% IBS Iberian 28 0 0.00% 1 3.57% 0 0.00% JPT Japanese 178 0 0.00% 1 0.56% 0 0.00% LWK Luhya 194 0 0.00% 0 0.00% 0 0.00% YRI Yoruban 176 0 0.00% 0 0.00% 0 0.00% 1000 Genomes Total 2166 76 3.51% 77 3.55% 83 3.83%

The A2 haplotype, comprised of closely related subtypes A2a and A2b, is uniquely tagged by rs2798235 and rs363080 in our 51-SNP panel as described above. 100 chromosomes in 1000 Genomes Phase I carry rs363080, of which 98 also carry rs2798235. The latter SNP is exclusively found on chromosomes tagged by rs363080, and no other chromosomes. High pairwise correlation between these two markers is similarly observed in direct genotyping of our Canadian HTT chromosomes (r²=0.98). In 1000 Genomes, three additional intragenic SNPs—rs363107, rs362313, and rs2530595—are found on 100, 99, and 99 of chromosomes bearing rs363080, respectively, and are likewise present only on these chromosomes. All five polymorphisms are present on 98% of chromosomes bearing any of the five variants, and therefore represent specific markers of the A2 haplotype (FIG. 1b ).

HD also commonly occurs on A3. In our 51-SNP panel, the A3 haplotype is defined by intragenic markers of the A haplo-group in the absence of SNPs specific for the other A haplotypes. 119 A3 haplotypes were identified out of 738 control chromosomes of European ancestry (16.1%). No identifying SNPs were found that uniquely encompass all 119 A3 chromosomes. However, a specific subtype SNP was observed on 45.4% (54/119) of A3 chromosomes—rs113407847—designating A3a (FIG. 1c ). In the 738 European individuals, rs113407847 is found only in the subset of A3 haplotypes. Despite common association with HD, no SNPs specific to both A1 and A3 were found, except when shared with other, non-HD associated A haplotypes.

Example 3 Validation of Polymorphisms Specific for the HTT A1 Haplotype

To validate the in silico association of all three A1-defining polymorphisms from low-coverage whole genome sequencing data in 1000 Genomes, Δ2642 and rs72239206 were directly genotyped and phased to the CAG repeat in HTT chromosomes previously genotyped for rs362307. These comprised all Canadian HD chromosomes genotyped with the original 63-SNP panel as well as other previously haplotyped samples from various ethnic groups. In total, 454 phased, nonredundant HD chromosomes and 652 nonredundant control chromosomes were successfully genotyped and phased to the CAG repeat at rs149109767 (Δ2642), and rs72239206. Pairwise LD of direct genotyping data indicates that all three polymorphisms are present in HD and control chromosomes in near-perfect LD (r2>0.99, TABLE 11) and that all three minor alleles are highly enriched on HD chromosomes versus controls.

TABLE 11 direct genotyping of a1 haplotype-defining alleles rs362307, rs149109767, rs72239206 in Caucasian HD and normal chromosomes from the UBC HD BioBank. HD Normal Chi-Square n % n % p = rs72239206 Δ 214 47.1% 42 6.4% 5.37E−204 (ΔACTT) ACTT 240 52.9% 610 93.6% Total 454 652 rs149109767 Δ 217 47.8% 43 6.6% 1.52E−204 (Δ2642) GAG 237 52.2% 609 93.4% Total 454 652 rs362307 T 216 47.6% 40 6.1% 4.09E−220 C 238 52.4% 612 93.9% Total 454 652

Marker studies of the Δ2642 codon deletion suggest that the frequency of the A1 haplotype varies considerably between Caucasian HD patient populations (i.e. Finnish, American, Swedish, Canadian, French, Croatian, Indian, Italian, Chinese and Japanese). A key question following our definition of specific gene-spanning HD haplotypes was therefore to determine the distribution of these haplotypes among different patient populations of European ancestry. A revised SNP panel was designed to include the prior 63-SNP panel as well as the novel defining A1, A2, and A3 SNPs derived from the 1000 Genomes Project. Using this revised panel, we genotyped 120 Swedish, 76 French, and 209 Italian HD family members, derived from respective countries of origin. Haplotypes were reconstructed and phased to CAG repeat size, in the same manner as the Canadian Caucasian cohort. All common 63-SNP haplotypes found in the Canadian Caucasian cohort were replicated by genotyping of the European HD cohorts using our revised panel. All three A1 variants and all five A2 variants conformed to high expected pairwise correlation in direct genotyping of the European cohorts with the revised panel (FIG. 1). Among all European patients, the CAG expansion on A3 was found exclusively in phase with the unique A3a-identifying SNP rs113407847, but not on A3b lacking this SNP, suggesting that A3a is a disease-associated haplotype. Direct genotyping of rs113407847 in Canadian HD A3 chromosomes similarly revealed that the CAG expansion occurs almost exclusively on A3a when present on A3 (31 of 34 A3 Canadian HD chromosomes). Common HD-associated haplotypes A1, A2, and A3a therefore share uniform sets of defining markers in ethnically distinct European HD patient cohorts, implying deep ancestral relationship of these disease-associated haplotypes across different European populations.

Whereas the sequence identity of intragenic HTT haplotypes is consistent across Caucasian HD patient populations, our direct genotyping reveals striking differences in frequency of specific HD-associated haplotypes among both CAG-expanded chromosomes and control chromosomes in different European populations. Among unrelated Swedish HD chromosomes, 51% (26/51) are found on A1, similar to our previously genotyped Canadian HD cohort (p=0.7616, Fisher's Exact). The frequency of A2 among Swedish HD is comparatively lower than in Canada (18% versus 32%, p=0.0455) and A3a is more frequent (28% versus 11% in Canadians, p=0.0033). French HD chromosomes are also most frequently A1 (45% versus 48%, p=0.7654) with A2 present at similar frequencies and A3a more common than in Canadian HD (A2, p=0.1957; A3a, p=0.0256). In contrast, Italian HD chromosomes are predominantly found on A2 (58%, p<0.000 i versus Canadian), with a much smaller proportion of HD on A1 versus the Canadian cohort (19%, p<0.0001) and a similar proportion of A3a (7%, p=0.2647). In a small set of Finnish HD families, haplotyped with our original 63-SNP panel, all unrelated disease chromosomes are A1 (6/10, 60%) or A2 (4/10, 40%). Despite differences in specific haplotype frequency between our Canadian and European cohorts, >90% of HD chromosomes are found on A1, A2, and A3a haplotypes in all four populations of Northern European ancestry and in 84% of Italian HD chromosomes. HTT haplotypes on control chromosomes also differ between European populations, though less dramatically than CAG-expanded chromosomes. The haplo-group trends toward higher frequency in Italian controls versus Canadian (p=0.0597), but is found at similar frequency among Swedish (p=0.6838) and French control chromosomes (p=0.8073). A1 occurs at statistically similar frequencies in all four control cohorts, whereas A2 occurs at higher frequency among Italian controls than in Canadian (24% versus 16%, p=0.0185) or Swedish controls (13%, p=0.0203), mirroring its elevated frequency among Italian HD chromosomes.

Example 4 A1, A2, and A3 Haplotypes Represent Optimal Target Panels for Allele-Specific HTT Silencing in HD Patient Populations

High pairwise correlation of specific haplotype-defining polymorphisms allows for targeting of the A1 and A2 haplotypes as a selective HTT silencing strategy. As all three A1 markers are present in near-perfect LD, targeting any single A1 polymorphism will allow allele-specific HTT silencing in a nearly equal number of HD patients heterozygous for this haplotype. Heterozygosity of A1 in HD patients, when phased to the CAG expansion, is highest in Sweden (47%), Canada (44%), and France (43%), but much lower in Italy (15%), suggesting greater utility in patients of Northern European ancestry (TABLE 12).

An estimated 98% of patients with HD on A2 (phased to rs3 63080) will have all five A2 targets present. The percent of patients heterozygous for A2, phased to the CAG expansion, range from to 18% in Sweden to 43% in Italy, suggesting a greater utility in Southern European populations. Tertiary targeting of rs113407847 would allow treatment of patients bearing the CAG expansion on A3a, ranging from a maximum of 27% of patients in Sweden to only 5% in Italy. In total, targeting three specific polymorphisms representing A1, A2, and A3a may allow selective silencing treatment of ˜80% of HD patients overall from the Canadian, Swedish, French, and Italian patient populations. Defining SNPs of these HD-associated haplotypes therefore represent panels of targets that could achieve ˜80% patient treatment by allele-specific HTT silencing strategies.

Example 5 ASOs Selectively Silence HTT A1 in Human Cells

Among all genotyped HD patients in this study, A1 is the most frequently heterozygous haplotype in cis with the expanded CAG repeat. The defining A1 markers rs362307, rs149109767 (Δ2642), and rs72239206 therefore represent allele-specific targets with the greatest heterozygosity in HD patients when the variant allele is phased to the CAG repeat expansion. Both rs362307 and rs149109767 (Δ2642) are found in mature mRNA, have known association with the CAG repeat expansion, and have been investigated as targets of siRNA-mediated selective HTT silencing [21, 30]. Unlike these variants, rs72239206 is intronic and has no previously reported association with the CAG expansion. We sought to evaluate the potential of rs72239206 as a selective HTT silencing target using ASOs directed to the mutant sequence.

In addition to offering a novel A1 target not previously associated with HD, we hypothesized that targeting of the 4 bp rs72239206 indel sequence may offer greater selectivity than discrimination by a single nucleotide polymorphism, and sought to evaluate the potential of rs72239206 as a selective mutant HTT silencing target. Unlike rs362307 and Δ2642, rs72239206 is located in an intron (intron 22 of HTT) and is therefore only targetable by agents complementary to un-spliced pre-mRNA. ASOs can induce RNAse H-mediated degradation of complementary pre-mRNA as well as mRNA, [31] and we therefore designed ASO sequences incorporating a gapmer design with locked nucleic acid (LNA) wings and phosphorothioate linkages complementary to the rs72239206 deletion sequence. (FIG. 3a ).

ASOs are passively taken up by neurons in primary culture [18]. In the absence of transgenic HTT neurons bearing rs72239206, we sought to test the silencing potential of LNA gapmers by passive uptake in human HD lymphoblasts bearing the A1 haplotype (GM03620, CAG 59/18). Remarkably, A1 HTT is selectively silenced in human lymphoblasts grown with rs2239206-targeted LNA gapmers in media, suggesting that lymphoblasts also passively take up ASO in culture. (FIG. 2 shows the A1/C1 lymphoblasts treated with a 5-9-5 LNA gapmer (SEQ ID NO: 36) and FIG. 5 shows the A1/C1 lymphoblasts treated with a 4-9-4 LNA gapmer (SEQ ID NO: 66). On the basis of these preliminary experiments, we sought to examine dose-dependent knockdown of A1 HTT mRNA and protein in HD patient lymphoblasts of typical CAG length using active transfection to maximize effective dose.

Transfection of human A1/C1 lymphoblasts with a 5-9-5 LNA gapmer (SEQ ID NO: 36) resulted in potent HTT mRNA silencing, but only minimal discrimination between A1 and C1 transcripts (11% A1 and 29% C1 HTT mRNA remaining at the highest dose versus untreated cells) (FIG. 3). Reduction of the DNA gap by two nucleotides to a 5-7-5 configuration (SEQ ID NO: 66) improved selectivity, with the HTT A1 transcript reduced to 29% of untreated mRNA levels at the highest dose versus 92% HTT C1 control. Shortening this molecule to a 4-7-4 LNA gapmer design (SEQ ID NO: 92) further improved selectivity for the HTT A1 transcript, reducing A1 HTT mRNA to 28.5% of untreated levels at the highest transfection dose while sparing HTT C1 mRNA (FIG. 3b ). Western blot analysis using allelic separation of CAG 44/18 bands revealed similar reduction at the protein level for all three LNA gapmer designs, inducing dose-dependent reduction of mutant HTT with 5-7-5 and 4-7-4 gapmers while sparing normal HTT (FIG. 3c ). Targeting the A1-specific rs72239206 deletion sequence with complementary ASOs can potently and selectively silence mutant HTT mRNA and protein in cells genetically representative of HD patients bearing the A1 haplotype.

Example 6 Targeting the rs72239206 Deletion Site is Efficacious and Tolerated In Vivo

In the absence of transgenic mice bearing the rs72239206 deletion in cis with expanded CAG, in vivo silencing of A1 HTT mRNA and protein could not be directly evaluated. However, the wild-type analog of the 5-9-5 LNA gapmer (SEQ ID NO: 36), designed against reference sequence that includes the four bases deleted in A1, also elicited potent reduction of human HTT in brains of YAC128 mice bearing transgenic full-length mutant HTT (FIG. 4). The rs72239206 deletion site is therefore accessible to ASO-mediated HTT mRNA silencing in vivo.

Example 7 ASOs silence HTT A2 in Human Cells

We sought to evaluate the potential of rs363107, rs362313 and rs2530595 as HTT silencing targets using ASOs directed to these mutant sequences. Specifically, rs36107 was targeted with a locked nucleic acid (LNA)/phosphorothioate backbone gapmer with sequence +T*+A*+T*+A*T*T*T*T*C*A*A*A*G*+A*+T*+C*+A (*=phosphorothioate linkages, +=LNA) (SEQ ID NO: 163); rs362313 was targeted with a locked nucleic acid (LNA)/phosphorothioate backbone gapmer with sequence +A*+A*+G*+A*C*A*T*C*A*C*T*G*T*+G*+A*+A*+G (*=phosphorothioate linkages, +=LNA) (SEQ ID NO: 268); and rs2530595 was targeted with a locked nucleic acid (LNA)/phosphorothioate backbone gapmer with sequence +T*+C*+C*+T*C*C*C*C*A*C*A*G*A*+G*+G*+G*+A (*=phosphorothioate linkages, +=LNA) (SEQ ID NO: 373). Human HD lymphoblasts bearing the A2/C haplotype (GM02150, CAG lengths 44/18) were treated with the LNA gapmer sequences at 0.5, 1, 2 and 5 μM for 120 hrs and harvested for Western blot analysis. As shown in FIGS. 6, 7 and 8, Western blot analysis using allelic separation of CAG 44/18 bands revealed reductions of mutant HTT at the protein level for all three LNA gapmer sequences. In summary, targeting the A2-specific polymorphisms (rs363107, rs362313 and rs2530595) with complementary ASOs can silence mutant HTT protein in cells genetically representative of HD patients bearing the A2 haplotype.

Example 8 ASOs Silence HTT A3a in Human Cells

We sought to evaluate the potential of rs113407847 as a selective HTT silencing target using ASO directed to the mutant sequence. Human HD lymphoblasts bearing the A3a/C haplotypes (GM04724, CAG lengths 67/15) were treated with a 4-9-4 locked nucleic acid (LNA)/phosphorothioate backbone gapmer with sequence +C*+T*+C*+C*C*C*A*C*C*T*C*C*C*+G*+G*+C*+C (*=phosphorothioate linkages, +=LNA) (SEQ ID NO: 478) at 0.5, 1, 2 and 5 μM for 120 hrs and harvested for Western blot analysis. As shown in FIG. 9, Western blot analysis using allelic separation of CAG 67/15 bands revealed a dose-dependent reduction of mutant HTT at the protein level. Targeting the A3a-specific rs113407847 with complementary ASOs can reduce the level of the mutant HTT protein in cells genetically representative of HD patients bearing the A3a haplotype.

Discussion

The translation of allele-specific HTT silencing to therapeutic application requires clarity as to which transcribed SNPs are the most useful targets in the HD patient population. The frequency of specific polymorphic targets is known to vary between clinical cohorts, while secondary and tertiary targets that maximize the total number of patients treatable have been incompletely described. Our study provides the first comprehensive heterozygosity estimates across the HTT transcript in multiple patient populations, identifying specific allele targets of highest priority for development of selective antisense therapies. We have fully described the most common gene-spanning haplotypes relevant for selective suppression of mutant HTT in patients of European ancestry—A1, A2, and A3a —and identify all common polymorphisms specific for these haplotypes. In four different patient populations, these gene-spanning haplotypes represent panels of allele-specific targets that would achieve treatment of the greatest proportion of HD patients. We show that as few as three gene silencing reagents targeting the A1, A2, and A3a haplotypes may offer allele-specific HTT silencing therapy for 80% of all patients of European descent. A1 may be silenced using one of three defining polymorphisms, and A2 using one of five defining polymorphisms. If only one allele target can be chosen for development, silencing the A haplogroup by rs2298969 may offer treatment in the greatest proportion of patients. But when two targets are considered additively, A1 and A2 targets in combination allow for treatment of the majority of patients in all four major populations evaluated in this study. When three targets are considered, no combination of intragenic polymorphisms allows for selective silencing in a greater proportion of cases than defining polymorphisms of the A1, A2, and A3a haplotypes. A1 and A2 haplotypes therefore represent sets of priority targets for preclinical evaluation of allele-specific HTT silencing reagents, with rs113407847 a priority tertiary candidate.

Expansion of the CAG repeat has been shown to occur on multiple haplotypes in different Caucasian populations [22, 24]. Here we demonstrate that three intragenic HTT haplotypes, identical across four different populations of European ancestry, account for approximately 90% of HD chromosomes across these groups. This suggests that haplotypes on which repeated CAG expansion events occur are ancestral to all individuals of European descent, and may perhaps be shared by other related populations. The Δ2642 codon deletion (rs149109767), identified here as an exclusive marker of the A1 haplotype, has been observed in HD patients and controls from India [32] whereas A1 is entirely absent among both HD and control chromosomes of black South Africans and East Asians where prevalence of HD is dramatically lower [28, 29]. This suggests that association of the A1 haplotype with HD may occur in all populations of Indo-European ancestry, spanning South Asia, Europe, and American populations of European descent. The frequency of HD on A1, A2, and A3a haplotypes requires detailed haplotype analysis in patient populations from the Middle East, Central Asia, South Asia, and Africa to evaluate the global therapeutic impact of these targets. The high prevalence of expanded CAG on A1, A2, and A3a among all patient populations of European descent, and the presence of these haplotypes in other ancestrally related populations, suggests that these haplotypes may allow allele-specific silencing in the maximum proportion of patients worldwide.

In summary, we show that HTT is defined by a gene-spanning haplotype block in populations of European descent, and that specific sets of SNPs define gene-spanning haplotypes in both HD patients and controls. To our knowledge, this is the first annotation of dense haplotypes encompassing the HTT gene using whole-genome sequencing data. We identify and validate all polymorphisms specific for the three most common HD haplotypes, comprising >90% of HD chromosomes in four distinct populations of European ancestry. The defining polymorphisms of these haplotypes constitute optimal targets for development of allele-specific silencing compounds. Targetable HTT haplotypes revealed by this study represent a crucial step toward that objective, and toward safe gene silencing treatment of the greatest number of HD patients.

Although various embodiments of the invention are disclosed herein, many adaptations and modifications may be made within the scope of the invention in accordance with the common general knowledge of those skilled in this art. Such modifications include the substitution of known equivalents for any aspect of the invention in order to achieve the same result in substantially the same way. Numeric ranges are inclusive of the numbers defining the range. The word “comprising” is used herein as an open-ended term, substantially equivalent to the phrase “including, but not limited to”, and the word “comprises” has a corresponding meaning. As used herein, the singular forms “a”, “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a thing” includes more than one such thing. Citation of references herein is not an admission that such references are prior art to an embodiment of the present invention. The invention includes all embodiments and variations substantially as hereinbefore described and with reference to the examples and drawings.

REFERENCES

1. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell, 1993. 72(6): p. 971-983.

2. Kremer, B., et al., A Worldwide Study of the Huntington's Disease Mutation: The Sensitivity and Specificity of Measuring CAG Repeats. New England Journal of Medicine, 1994. 330(20): p. 1401-1406.

3. Rubinsztein, D. C., et al., Phenotypic Characterization of Individuals with 30-40 CAG Repeats in the Huntington Disease (HD) Gene Reveals HD Cases with 36 Repeats and Apparently Normal Elderly Individuals with 36-39 Repeats. American Journal of Human Genetics, 1996. 59(1): p. 16-22.

4. Zuccato, C., M. Valenza, and E. Cattaneo, Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease. Physiological Reviews, 2010. 90(3): p. 905-981.

5. Southwell, A. L., et al., Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends in Molecular Medicine, 2012. 18(11): p. 634-643.

6. Yamamoto, A., J. J. Lucas, and R. Hen, Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease. Cell, 2000. 101(1): p. 57-66.

7. Kordasiewicz, H. B., et al., Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis. Neuron, 2012. 74(6): p. 1031-1044.

8. Harper, S. Q., et al., RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. PNAS, 2005. 102(16): p. 5820-5825.

9. Rodriguez-Lebron, E., et al., Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1Huntington's disease transgenic mice. Mol Ther, 2005. 12(4): p. 618-633.

10. Nasir, J., et al., Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell, 1995. 81(5): p. 811.-823.

11. Duyao, M. P., et al., Inactivation of the Mouse Huntington's Disease Gene Homolog Hdh. Science, 1995. 269(5222): p. 407-410.

12. Zeitlin, S., et al., Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nature Genetics, 1995. 11(2): p. 155-163.

13. Auerbach, W., et al., The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin. Human Molecular Genetics, 2001. 10(22): p. 2515-23.

14. Sah, D. W. Y. and N. Aronin, Oligonucleotide therapeutic approaches for Huntington disease. The Journal of Clinical Investigation, 2011. 121(2): p. 500-507.

15. Kay, C., et al., Personalized gene silencing therapeutics for Huntington disease. Clinical Genetics, 2014. 86(1): p. 29-36.

16. Yu, D., et al., Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression. Cell, 2012. 150(5): p. 895-908.

17. Fiszer, A., et al., Self-duplexing CUG repeats selectively inhibit mutant huntingtin expression. Nucleic Acids Res, 2013. 41(22): p. 10426-37.

18. Carroll, J. B., et al., Potent and Selective Antisense Oligonucleotides Targeting Single-Nucleotide Polymorphisms in the Huntington Disease Gene/Allele-Specific Silencing of Mutant Huntingtin. Mol Ther, 2011. 19: p. 2178-2185.

19. Southwell, A. L., et al., In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Mol Ther, 2014.

20. Ostergaard, M. E., et al., Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res, 2013. 41(21): p. 9634-50.

21. Zhang, Y., J. Engelman, and R. M. Friedlander, Allele-specific silencing of mutant Huntington's disease gene. Journal of Neurochemistry, 2009. 108(1): p. 82-90.

22. Lee, J.-M., et al., Common SNP-Based Haplotype Analysis of the 4p16.3 Huntington Disease Gene Region. American Journal of Human Genetics, 2012. 90(3): p. 434-444.

23. Novelletto, A., et al., Analysis of the trinucleotide repeat expansion in Italian families affected with Huntington disease. Human Molecular Genetics, 1994. 3(1): p. 93-8.

24. Warby, S. C., et al., CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. American Journal of Human Genetics, 2009. 84(3): p. 351-366.

25. Skotte, N. H., et al., Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients. PLoS One, 2014. 9(9): p. e107434.

26. Slow, E. J., et al., Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet, 2003. 12(13): p. 1555-67.

27. Abecasis, G. R., et al., An integrated map of genetic variation from 1,092 human genomes. Nature, 2012. 491(7422): p. 56-65.

28. Baine, F. K., et al., Huntington disease in the South African population occurs on diverse and ethnically distinct genetic haplotypes. European Journal of Human Genetics, 2013. 21(10): p. 1120-7.

29. Warby, S. C., et al., HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia. European Journal of Human Genetics, 2011. 19(5): p. 561-566.

30. Pfister, E. L., et al., Five siRNAs Targeting Three SNPs May Provide Therapy for Three-Quarters of Huntington's Disease Patients. Current Biology, 2009. 19(9): p. 774-778.

31. Bennett, C. F. and E. E. Swayze, RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annual Review of Pharmacology and Toxicology, 2010. 50: p. 259-293.

32. Saleem, Q., et al., Molecular analysis of Huntington's disease and linked polymorphisms in the Indian population. Acta Neurologica Scandinavica, 2003. 108(4): p. 281-6. 

1. An oligomer of between 10-30 nucleobases in length which comprises a contiguous nucleotide sequence of a total of between 10-26 nucleotides, wherein the continuous nucleotide sequence is targeted to hybridize to a sequence selected from the group consisting of: (SEQ ID NO: 522) 5′-TGACAGTTGTATTTTTGTTTGTGACACGTATTATCTGTTAAAACATT TTC-3′; (SEQ ID NO: 523) 5′-TCTTAAACTTTTAAATGCCATTTGATCTTTGAAAATATATGTTTTAA TAGTGTATTTTAAG-3′; (SEQ ID NO: 524) 5′-CCCTCAGCGAGCAAGTCAAGCTCTTCACAGTGATGTCTTACAAGCGC AGAGGGCTCTGTGA-3′; (SEQ ID NO: 525) 5′-GCTTTGTCCCTCCCCCGCTTCCTCCCTCTGTGGGGAGGACCCGGGAC CACAGCTGCTGGCC-3′; and (SEQ ID NO: 526) 5′-GGAGAGACTCCACTCTGAATGGGGCCGGGAGGTGGGGAGGACTCCAT TTCAGATGGGGTCG-3′;

wherein the oligomer targets the bolded nucleotide(s), permits between 0-3 mismatches and reduces mutant Huntingtin (HTT) mRNA or mutant HTT protein in a cell or tissue.
 2. The oligomer of claim 1, wherein the oligomer is selected from SEQ ID NOs: 6-10.
 3. The oligomer of claim 1 or 2, wherein the oligomer is selected from SEQ ID NOs: 11-517.
 4. The oligomer of claim 1, 2 or 3, wherein the oligomer has a sequence selected from the group consisting of: (SEQ ID NO: 36) 5′-GATAATACGTGTCACAAAC-3′; (SEQ ID NO: 66) 5′-ATAATACGTGTCACAAA-3′; (SEQ ID NO: 92) 5′-TAATACGTGTCACAA-3′; (SEQ ID NO: 163) 5′-TATATTTTCAAAGATCA-3′; (SEQ ID NO: 268) 5′-AAGACATCACTGTGAAG-3′; (SEQ ID NO: 373) 5′-TCCTCCCCACAGAGGGA-3′; and (SEQ ID NO: 478) 5′-CTCCCCACCTCCCGGCC-3′.


5. The oligomer of any one of claims 1-4, wherein the contiguous nucleotide sequence comprises nucleotide analogues.
 6. The oligomer of any one of claims 1-5, wherein the oligomer has a modified internucleoside linkage.
 7. The oligomer of claim 6, wherein the modified internucleoside linkage is a peptide-nucleic acid linkage, a morpholino linkage, a N3′ to P5′ phosphoramidate linkage, a methylphosphonate linkage or a phosphorothioate linkage.
 8. The oligomer of any one of claims 1-7, wherein the oligomer has one or more modified sugar moiety.
 9. The oligomer of claim 8, wherein the modified sugar moiety is 2′-O-alkyl oligoribonucleotide.
 10. The oligomer of any one of claims 1-9, wherein the oligomer is a gapmer.
 11. The oligomer of claim 9, wherein the oligomer has a 2′MOE gapmer modification.
 12. The oligomer of any one of claims 1-11, wherein the oligomer has a modified nucleobase.
 13. The oligomer of claim 12, wherein the modified nucleobase is a 5-methyl pyrimidine or a 5-propynyl pyrimidine.
 14. The oligomer of claim 8, wherein the one or more nucleotide analogues comprise locked nucleic acids (LNA) units.
 15. The oligomer according to claim 13 or 14, wherein the LNA units consist of beta-D-oxy-LNA monomers.
 16. A pharmaceutical composition comprising the oligomer of any one of claims 1-15 and a pharmaceutically acceptable diluent, carrier, salt or adjuvant.
 17. A method of reducing mutant Huntingtin (HTT) mRNA or mutant HTT protein in a cell or tissue, comprising contacting the cell or tissue with an effective amount of an oligomer targeting a differentiating polymorphism, wherein the differentiating polymorphism is selected from rs72239206, rs363107, rs362313, rs2530595, rs113407847.
 18. A method reducing mutant Huntingtin (HTT) mRNA or mutant HTT protein in a cell or tissue, comprising contacting the cell or tissue with an effective amount of an oligomer of any one of claims 1-15 or a pharmaceutical composition of claim
 16. 19. The method of claim 17 or 18, wherein the cell is within a tissue of a mammal.
 20. A method of treating Huntington Disease (HD) in a mammal, comprising administering to the mammal an effective amount of an oligomer targeting a differentiating polymorphism, wherein the differentiating polymorphism is selected from rs72239206, rs363107, rs362313, rs2530595, rs113407847.
 21. A method of treating a Huntington Disease (HD) in a mammal, comprising administering to the mammal an effective amount of an oligomer of any one of claims 1-15; or a pharmaceutical composition of claim 16; wherein the mammal is currently suffering from or at risk of suffering from HD.
 22. The method of claim 19, 20 or 21, wherein the mammal is a human.
 23. Use of an oligomer of any one of claims 1-15 in the preparation of a medicament for the treatment of HD.
 24. Use of an oligomer for the treatment of HD, wherein the oligomer targets a differentiating polymorphism, wherein the differentiating polymorphism is selected from rs72239206, rs363107, rs362313, rs2530595, rs113407847.
 25. Use of an oligomer of any one of claims 1-15 for the treatment of HD.
 26. Use of a pharmaceutical composition of claim 16 for the treatment of HD.
 27. An oligomer of any one of claims 1-15 for use in the treatment of HD.
 28. A commercial package, comprising: a. an oligomer of any one of claims i-is; and b. instructions for the treatment of HD. 